FDA Drug Shortages

Updated daily

Last refreshed: October 25, 2026
Drugs tracked: 482
Currently in shortage: 285 Drugs
Source: FDA DSS

Updated Daily October 25, 2026

The full list

Drug shortages by status

Our full list of 482 drug products tracked by the FDA, each carrying one of the three statuses below. Search, sort, or filter the list — click a status card to filter by status, or expand a row for package-level detail. Please note that the list changes constantly and could contain errors.

Details	Generic Name	Company Name	Therapeutic Category	Date of Update	Status
	Clonazepam Tablet	Teva Pharmaceuticals USA, Inc.	Neurology Pediatric Psychiatry	2026-10-23	Currently in Shortage
First posted by the FDA 2023-03-10 Presentations affected 6 Manufacturer contact 800-545-8800 Clonazepam, Tablet, .5 mg (NDC 0093-0832-01) Available Clonazepam, Tablet, .5 mg (NDC 0093-0832-05) Available Clonazepam, Tablet, 1 mg (NDC 0093-3212-01) Available Clonazepam, Tablet, 1 mg (NDC 0093-3212-05) Available Clonazepam, Tablet, 2 mg (NDC 0093-3213-01) Available Clonazepam, Tablet, 2 mg (NDC 0093-3213-05) Available
	Metformin Hydrochloride Tablet, Extended Release	Mylan Pharmaceuticals Inc., a Viatris Company	Endocrinology/Metabolism	2026-10-22	To Be Discontinued
First posted by the FDA 2026-10-22 Presentations affected 2 Manufacturer contact 800-796-9526 Metformin Hydrochloride, Tablet, Extended Release, 1000 mg (NDC 0378-6001-91) A business decision was made was discontinue manufacture of the drug product. Metformin Hydrochloride, Tablet, Extended Release, 500 mg (NDC 0378-6002-91) A business decision was made was discontinue manufacture of the drug product.
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Sandoz Inc.	Psychiatry	2026-10-21	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 4 Manufacturer contact 800-525-8747 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01) Available
	Atropine Sulfate Injection	Hospira, Inc., a Pfizer Company	Anesthesia Neurology Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 2 Manufacturer contact 844-646-4398 Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05) Available Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10) Limited Availability Other
	Bupivacaine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 20 Manufacturer contact 844-646-4398 Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01) Available Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02) Available Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02) Available Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01) Available Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01) Available Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01) Available Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01) Available Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02) Available Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01) Available Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10) Unavailable Other Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62) Available Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01) Available Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25) Available Historical NDC: 0409-1582-29 Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01) Available Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25) Available Historical NDC: 0409-1610-50 Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01) Available Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01) Available Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01) Available Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01) Available Historical NDC: 0409-1582-29 Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1165-01) Available
	Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection	Hospira, Inc., a Pfizer Company	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 12 Manufacturer contact 844-646-4398 Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01) Unavailable Other Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17) Unavailable Other Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01) Unavailable Other Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01) Unavailable Other Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01) Unavailable Other Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17) Unavailable Other Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50) Limited Availability Other Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29) Available Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10) Available Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50) Available Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10) Available Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30) Available
	Carboplatin Injection	Gland Pharma Limited	Oncology	2026-10-21	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 4 Manufacturer contact Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270 Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) Available Distributed by BPI Labs, LLC Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) Limited Availability Demand increase for the drug Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) Unavailable Discontinuation of the manufacture of the drug Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) Limited Availability Demand increase for the drug
	Clindamycin Phosphate Injection	Pfizer Inc.	Anti-Infective	2026-10-21	Currently in Shortage
First posted by the FDA 2023-03-21 Presentations affected 3 Manufacturer contact 800-533-4535 Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26) Unavailable Other More from the FDA Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26) Unavailable Other More from the FDA Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18) Unavailable Other More from the FDA
	Clindamycin Phosphate Injection	Sandoz Inc.	Anti-Infective	2026-10-21	Currently in Shortage
First posted by the FDA 2023-03-21 Presentations affected 5 Manufacturer contact 800-525-8747 Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09) Available Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24) Available Civica Label Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09) Available Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24) Available Civica Label Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09) Available
	Dexmedetomidine Hydrochloride Injection	Gland Pharma Limited	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 3 Manufacturer contact 855-273-0154 Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42) Available Marketed by Piramal Critical Care Inc.: 800-414-1901 Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58) Available Distributed by DRL Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58) Available Distributed by DRL
	Dexmedetomidine Hydrochloride Injection	Pfizer Inc.	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 14 Manufacturer contact 844-646-4398 Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01) Available Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01) Available Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20) Available Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50) Available Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20) Available Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24) Available Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02) Available Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10) Available Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10) Available Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24) Available Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10) Limited Availability Other Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12) Available Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20) Available Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02) Available
	Dextrose Monohydrate 50% Injection	Hospira, Inc., a Pfizer Company	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2022-01-13 Presentations affected 2 Manufacturer contact 844-646-4398 Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02) Limited Availability Other Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16) Unavailable Other
	Dobutamine Hydrochloride Injection	Hainan Poly Pharm. Co., Ltd.	Cardiovascular Pediatric Renal	2026-10-21	Currently in Shortage
First posted by the FDA 2017-11-06 Presentations affected 1 Manufacturer contact Slate Run Pharmaceuticals, LLC: 844-529-8988 Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80) Available Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988
	Dobutamine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Cardiovascular Pediatric Renal	2026-10-21	Currently in Shortage
First posted by the FDA 2017-11-06 Presentations affected 6 Manufacturer contact 844-646-4398 Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (4 mg/mL) (NDC 0409-1100-10) Available Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (1 mg/mL) (NDC 0409-0025-10) Available Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (2 mg/mL) (NDC 0409-0151-10) Available Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01) Available Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02) Available Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88) Unavailable Other
	Dopamine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Cardiovascular	2026-10-21	Currently in Shortage
First posted by the FDA 2017-11-06 Presentations affected 5 Manufacturer contact 844-646-4398 Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12) Available Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12) Available Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24) Unavailable Other Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01) Available Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20) Available
	Epinephrine Bitartrate, Lidocaine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Anesthesia Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2012-02-22 Presentations affected 10 Manufacturer contact 844-646-4398 Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03) Limited Availability Other Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01) Limited Availability Other Lidocaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01) Unavailable Other Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02) Unavailable Other Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01) Unavailable Other Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01) Limited Availability Other Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01) Limited Availalbility Other Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03) Limited Availability Other Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02) Limited Availability Other Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01) Unavailable Other
	Etomidate Injection	Gland Pharma Limited	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2022-10-05 Presentations affected 2 Manufacturer contact 833-291-9645 Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10) Available Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10) Available Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.
	Etomidate Injection	Hospira, Inc., a Pfizer Company	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2022-10-05 Presentations affected 2 Manufacturer contact 844-646-4398 Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01) Unavailable Other Amidate, Injection, 2 mg/mL (NDC 0409-6695-02) Unavailable Other
	Fentanyl Citrate Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 6 Manufacturer contact 844-646-4398 Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22) Available Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31) Limited Availability Demand increase for the drug Fentanyl Citrate, Injection, 2,500 mcg/50 mL (50 mcg/mL) Single Dose Glass Fliptop Vial (NDC 0409-9094-55) Available Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25) Limited Availability Demand increase for the drug Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61) Available Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28) Limited Availability Demand increase for the drug
	Furosemide Injection	Gland Pharma Limited	Cardiovascular	2026-10-21	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 866-625-1618 Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) Unavailable Discontinuation of the manufacture of the drug More from the FDA Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) Unavailable Discontinuation of the manufacture of the drug More from the FDA Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) Unavailable Discontinuation of the manufacture of the drug More from the FDA
	Furosemide Injection	Hospira, Inc., a Pfizer Company	Cardiovascular	2026-10-21	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 6 Manufacturer contact 844-646-4398 Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10) Available Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02) Available Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04) Available Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27) Unavailable Other Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25) Unavailable Other Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26) Unavailable Other
	Heparin Sodium Injection	Hospira, Inc., a Pfizer Company	Hematology	2026-10-21	Currently in Shortage
First posted by the FDA 2017-11-14 Presentations affected 2 Manufacturer contact 844-646-4398 Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20) Available Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12) Available
	Hydromorphone Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction	2026-10-21	Currently in Shortage
First posted by the FDA 2017-10-31 Presentations affected 11 Manufacturer contact 844-646-4398 Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01) Unavailable Other Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01) Limited Availability Other Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37) Unavailable Other Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31) Available Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01) Available Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36) Limited Availability Other Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10) Available Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30) Available Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31) Available Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05) Available Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50) Available
	Ketorolac Tromethamine Injection	Gland Pharma Limited	Analgesia/Addiction	2026-10-21	Currently in Shortage
First posted by the FDA 2018-03-23 Presentations affected 5 Manufacturer contact 833-291-9645 Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01) Available Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01) Available Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02) Available Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25) Available Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645. Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25) Available Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.
	Ketorolac Tromethamine Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction	2026-10-21	Currently in Shortage
First posted by the FDA 2018-03-26 Presentations affected 3 Manufacturer contact 844-646-4398 Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01) Unavailable Other Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01) Unavailable Other Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01) Unavailable Other
	Lidocaine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Anesthesia Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2012-02-22 Presentations affected 16 Manufacturer contact 844-646-4398 Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02) Available Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01) Available Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01) Unavailable Other Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01) Available Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02) Available Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05) Limited Availability Other Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05) Available Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32) Unavailable Other Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01) Available Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01) Available Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02) Available Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05) Available Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02) Available Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01) Available Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02) Available Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01) Available
	Lorazepam Injection	Hospira, Inc., a Pfizer Company	Neurology	2026-10-21	Currently in Shortage
First posted by the FDA 2018-05-03 Presentations affected 1 Manufacturer contact 844-646-4398 Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30) Limited Availability Demand increase for the drug
	Meperidine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction	2026-10-21	Currently in Shortage
First posted by the FDA 2025-05-30 Presentations affected 3 Manufacturer contact 844-646-4398 Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30) Available Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30) Available Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30) Available
	Methotrexate Sodium Injection	Hospira, Inc., a Pfizer Company	Oncology Rheumatology	2026-10-21	Currently in Shortage
First posted by the FDA 2023-03-13 Presentations affected 5 Manufacturer contact 844-646-4398 Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) Available Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) Available Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) Available Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) Available Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) Available
	Methylprednisolone Acetate Injection	Pfizer Inc.	Rheumatology	2026-10-21	Currently in Shortage
First posted by the FDA 2021-12-15 Presentations affected 13 Manufacturer contact 844-646-4398 Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01) Available Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02) Unavailable Demand increase for the drug Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03) Limited Availability Other Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51) Limited Availability Demand increase for the drug Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52) Available Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01) Limited Availability Demand increase for the drug Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03) Limited Availability Other Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22) Available Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23) Available Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02) Available Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12) Available Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01) Limited Availability Demand increase for the drug Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03) Limited Availability Other
	Metronidazole Injection	Gland Pharma Limited	Anti-Infective	2026-10-21	Currently in Shortage
First posted by the FDA 2022-01-13 Presentations affected 1 Manufacturer contact Distributed by Sun Pharma Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01) Unavailable Discontinuation of the manufacture of the drug
	Midazolam Hydrochloride Injection	Gland Pharma Limited	Anesthesia Neurology	2026-10-21	Currently in Shortage
First posted by the FDA 2020-04-02 Presentations affected 2 Manufacturer contact Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618 Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02) Unavailable Other Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10) Unavailable Other
	Midazolam Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Anesthesia Neurology	2026-10-21	Currently in Shortage
First posted by the FDA 2020-04-02 Presentations affected 8 Manufacturer contact 844-646-4398 Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02) Unavailable Demand increase for the drug Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25) Limited Availability Demand increase for the drug Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17) Limited Availability Demand increase for the drug Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05) Limited Availability Demand increase for the drug Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01) Unavailable Demand increase for the drug Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05) Unavailable Demand increase for the drug Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03) Available Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05) Available
	Morphine Sulfate Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction	2026-10-21	Currently in Shortage
First posted by the FDA 2017-10-31 Presentations affected 8 Manufacturer contact 844-646-4398 Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01) Unavailable Discontinuation of the manufacture of the drug Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12) Limited Availability Other Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23) Limited Availability Other Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01) Available Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01) Available Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12) Available Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20) Unavailable Other Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01) Unavailable Other
	Penicillin G Benzathine Injection	Pfizer Inc.	Anti-Infective	2026-10-21	Currently in Shortage
First posted by the FDA 2023-04-26 Presentations affected 3 Manufacturer contact 800-533-4535 Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10) Limited Availability Other More from the FDA Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10) Limited Availability Other More from the FDA Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10) Unavailable Other More from the FDA
	Pentostatin Injection	Hospira, Inc., a Pfizer Company	Oncology	2026-10-21	Currently in Shortage
First posted by the FDA 2026-08-27 Presentations affected 1 Manufacturer contact 844-646-4398 Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01) Unavailable Other
	Rocuronium Bromide Injection	Hospira, Inc., a Pfizer Company	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 4 Manufacturer contact 844-646-4398 Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10) Available Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10) Available Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10) Available Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10) Available
	Rocuronium Bromide Injection	Sandoz Inc.	Anesthesia	2026-10-21	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 800-525-8747 Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92) Available Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95) Available
	Sodium Acetate Injection	Hospira, Inc., a Pfizer Company	Endocrinology/Metabolism Gastroenterology Pediatric Total Parenteral Nutrition	2026-10-21	Currently in Shortage
First posted by the FDA 2016-02-03 Presentations affected 6 Manufacturer contact 844-646-4398 Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05) Available Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26) Available Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06) Available Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25) Available Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25) Available Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73) Available
	Sodium Bicarbonate Injection	Hospira, Inc., a Pfizer Company	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2017-03-01 Presentations affected 4 Manufacturer contact 844-646-4398 Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01) Limited Supply Available. Next Delivery and Estimated Recovery: June 2027 Other Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02) Limited Availability Demand increase for the drug Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14) Available Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35) Unavailable Other
	Sterile Water Injection	Hospira, Inc., a Pfizer Company	Other	2026-10-21	Currently in Shortage
First posted by the FDA 2021-11-23 Presentations affected 5 Manufacturer contact 844-646-4398 Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03) Available Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10) Available Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20) Available Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50) Available Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99) Available
	Sufentanil Citrate Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction Pediatric	2026-10-21	Currently in Shortage
First posted by the FDA 2022-05-03 Presentations affected 1 Manufacturer contact 844-646-4398 Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21) Limited Availability Other
	Azacitidine Injection	Dr. Reddy's Laboratories, Inc.	Oncology	2026-10-20	Currently in Shortage
First posted by the FDA 2020-12-18 Presentations affected 1 Manufacturer contact 866-732-3952 Azacitidine, Injection, 100 mg (NDC 43598-305-62) Available Available to existing customers
	Carboplatin Injection	Teyro Labs	Oncology	2026-10-20	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 4 Manufacturer contact Natco Pharma USA LLC: (201)786-6500 Carboplatin, Injection, 150 mg/15 mL (NDC 69339-365-15) Available Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC) Carboplatin, Injection, 450 mg/45 mL (NDC 69339-366-45) Available Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC) Carboplatin, Injection, 50 mg/5 mL (NDC 69339-364-05) Available Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC) Carboplatin, Injection, 600 mg/60 mL (NDC 69339-367-60) Available Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC)
	Enoxaparin Sodium Injection	Sanofi-Aventis U.S. LLC	Hematology	2026-10-20	To Be Discontinued
First posted by the FDA 2026-10-20 Presentations affected 24 Manufacturer contact 800-631-1610 Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 60 mg/.6 mL (NDC 0955-1006-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Enoxaparin Sodium, Injection, 80 mg/.8 mL (NDC 0955-1008-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 120 mg/.8 mL (NDC 0075-2912-01) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 120 mg/.8 mL (NDC 0075-8022-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 150 mg/1 mL (NDC 0075-8025-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 30 mg/.3 mL (NDC 0075-8013-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 300 mg/3 mL (NDC 0075-8030-01) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 40 mg/.4 mL (NDC 0075-0620-40) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 60 mg/.6 mL (NDC 0075-0621-60) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 60 mg/.6 mL (NDC 0075-8016-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 80 mg/.8 mL (NDC 0075-0622-80) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. Lovenox, Injection, 80 mg/.8 mL (NDC 0075-8018-10) Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
	Leuprolide Acetate Injection	Amneal Pharmaceuticals	Oncology	2026-10-20	To Be Discontinued
First posted by the FDA 2026-10-20 Presentations affected 1 Manufacturer contact 866.525.7270 Leuprolide Acetate, Injection, 14 mg/2.8 mL (1 mg/0.2 mL) (NDC 70121-2537-6) A business decision was made to discontinue manufacture of the drug.
	Methylphenidate Hydrochloride Tablet, Extended Release	Janssen Pharmaceuticals	Psychiatry	2026-10-20	Currently in Shortage
First posted by the FDA 2023-07-26 Presentations affected 4 Manufacturer contact 800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) Available Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) Available Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) Available Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) Available
	Molnupiravir Capsule	Merck Sharp & Dohme LLC	Anti-Infective Antiviral	2026-10-20	To Be Discontinued
First posted by the FDA 2026-10-20 Presentations affected 3 Manufacturer contact 800-672-6372 Lagevrio, Capsule, 200 mg (NDC 0006-5055-06) Discontinuation of the manufacture of the drug Lagevrio, Capsule, 200 mg (NDC 0006-5055-07) Discontinuation of the manufacture of the drug Lagevrio, Capsule, 200 mg (NDC 0006-5055-09) Discontinuation of the manufacture of the drug
	Amino Acid Injection	B. Braun Medical Inc.	Gastroenterology	2026-10-19	Currently in Shortage
First posted by the FDA 2020-12-08 Presentations affected 3 Manufacturer contact 800-227-2862 Plenamine, Injection, 0.15 (NDC 0264-4500-00) Available Plenamine, Injection, 0.15 (NDC 0264-4500-05) Available TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10) Available
	Azacitidine Injection	Eugia US LLC	Oncology	2026-10-19	Currently in Shortage
First posted by the FDA 2020-12-22 Presentations affected 1 Manufacturer contact 888-238-7880 Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01) Unavailable Demand increase for the drug
	Bupivacaine Hydrochloride Injection	Eugia US LLC	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 8 Manufacturer contact 888-238-7880 Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10) Available Check wholesalers for inventory Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30) Available Check wholesalers for inventory
	Carboplatin Injection	Eugia US LLC	Oncology	2026-10-19	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 2 Manufacturer contact 888-238-7880 Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) Unavailable Demand increase for the drug Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) Available Check wholesalers for inventory
	Cromolyn Sodium Concentrate	Mylan Specialty, a Viatris Company	Pulmonary/Allergy	2026-10-19	Currently in Shortage
First posted by the FDA 2023-11-03 Presentations affected 1 Manufacturer contact (800) 796-9526 Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96) Available
	Dexamethasone Sodium Phosphate Injection	Eugia US LLC	Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Other Pulmonary/Allergy Rheumatology	2026-10-19	Currently in Shortage
First posted by the FDA 2019-02-08 Presentations affected 1 Manufacturer contact 888-238-7880 Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25) Available Check wholesalers for inventory
	Dexamethasone Sodium Phosphate Injection	Mylan Institutional, a Viatris Company	Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Other Pulmonary/Allergy Rheumatology	2026-10-19	Currently in Shortage
First posted by the FDA 2019-02-08 Presentations affected 4 Manufacturer contact 800-796-9526 Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) Available Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30) Available Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) Available Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) Available
	Dexmedetomidine Hydrochloride Injection	Eugia US LLC	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 3 Manufacturer contact 888-238-7880 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02) Available Check wholesalers for inventory Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10) Available Check wholesalers for inventory Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10) Available Check wholesalers for inventory
	Dexmedetomidine Hydrochloride Injection	Mylan Institutional, a Viatris Company	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 3 Manufacturer contact 800-796-9526 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02) Available Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50) Available Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10) Available
	Dextrose Monohydrate 10% Injection	B. Braun Medical Inc.	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-19	Currently in Shortage
First posted by the FDA 2022-03-01 Presentations affected 3 Manufacturer contact 800-227-2862 Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00) Available Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10) Available Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20) Available
	Dextrose Monohydrate 5% Injection	B. Braun Medical Inc.	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-19	Currently in Shortage
First posted by the FDA 2022-02-14 Presentations affected 5 Manufacturer contact 800-227-2862 Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31) Available Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32) Available Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00) Available Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10) Available Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20) Available
	Dextrose Monohydrate 70% Injection	B. Braun Medical Inc.	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-19	Currently in Shortage
First posted by the FDA 2024-10-11 Presentations affected 1 Manufacturer contact 800-227-2862 Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50) Available
	Etomidate Injection	Eugia US LLC	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2022-10-05 Presentations affected 2 Manufacturer contact 888-238-7880 Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10) Unavailable Demand increase for the drug Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20) Unavailable Demand increase for the drug
	Etomidate Injection	Mylan Institutional, a Viatris Company	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2022-10-05 Presentations affected 2 Manufacturer contact 800-796-9526 Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10) Unavailable Demand increase for the drug Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20) Available
	Furosemide Injection	Eugia US LLC	Cardiovascular	2026-10-19	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 888-238-7880 Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25) Available Check wholesalers for inventory Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25) Unavailable Demand increase for the drug Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25) Available Check wholesalers for inventory
	Heparin Sodium Injection	B. Braun Medical Inc.	Hematology	2026-10-19	Currently in Shortage
First posted by the FDA 2017-11-14 Presentations affected 2 Manufacturer contact 800-227-2862 Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10) Limited Availability Other Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00) Limited Availability Other
	Hydroxocobalamin Injection	BTG International Inc.	Other	2026-10-19	Currently in Shortage
First posted by the FDA 2024-11-04 Presentations affected 1 Manufacturer contact 1 877 377 3784 Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11) Limited Availability Other More from the FDA
	Lamivudine Tablet	ViiV Healthcare Company	Antiviral	2026-10-19	To Be Discontinued
First posted by the FDA 2026-10-19 Presentations affected 2 Manufacturer contact 800-844-8872 Epivir, Tablet, 150 mg (NDC 49702-203-18) The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug Epivir, Tablet, 300 mg (NDC 49702-204-13) The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
	Lidocaine Hydrochloride Injection	B. Braun Medical Inc.	Cardiovascular	2026-10-19	Currently in Shortage
First posted by the FDA 2017-10-25 Presentations affected 3 Manufacturer contact 800-227-2862 Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10) Available Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20) Available Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20) Available
	Lidocaine Hydrochloride Injection	Eugia US LLC	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 11 Manufacturer contact 888-238-7880 Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02) Available Check wholesalers for inventory Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05) Available Check wholesalers for inventory Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30) Available Check wholesalers for inventory Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10) Available Check wholesalers for inventory Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02) Available Check wholesalers for inventory Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20) Available Check wholesalers for inventory Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50) Unavailable Demand increase for the drug
	Lisdexamfetamine Dimesylate Capsule	Mylan Pharmaceuticals Inc., a Viatris Company	Psychiatry	2026-10-19	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 800-796-9526 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77) Available Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77) Available Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77) Available Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77) Available
	Lisdexamfetamine Dimesylate Capsule	Sun Pharmaceutical Industries, Inc.	Psychiatry	2026-10-19	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 800-818-4555 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 57664-047-88) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88) Limited Availability Other
	Lisdexamfetamine Dimesylate Tablet, Chewable	Sun Pharmaceutical Industries, Inc.	Psychiatry	2026-10-19	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 6 Manufacturer contact 800-818-4555 Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88) Available
	Methylphenidate Hydrochloride Tablet, Extended Release	Sun Pharmaceutical Industries, Inc.	Psychiatry	2026-10-19	Currently in Shortage
First posted by the FDA 2023-07-26 Presentations affected 4 Manufacturer contact 800-818-4555 Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) Unavailable Discontinuation of the manufacture of the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) Unavailable Discontinuation of the manufacture of the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) Unavailable Discontinuation of the manufacture of the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) Unavailable Discontinuation of the manufacture of the drug
	Methylprednisolone Acetate Injection	Eugia US LLC	Rheumatology	2026-10-19	Currently in Shortage
First posted by the FDA 2021-12-15 Presentations affected 2 Manufacturer contact 888-238-7880 Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01) Unavailable Demand increase for the drug Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01) Unavailable Demand increase for the drug
	Remifentanil Hydrochloride Injection	Mylan Institutional, a Viatris Company	Analgesia/Addiction	2026-10-19	Currently in Shortage
First posted by the FDA 2022-06-28 Presentations affected 3 Manufacturer contact 800-796-9526 Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) Available Ultiva, Injection, 2 mg (NDC 72078-035-02) Available Ultiva, Injection, 5 mg (NDC 72078-036-05) Available
	Rifampin Injection	Mylan Institutional, a Viatris Company	Anti-Infective	2026-10-19	Currently in Shortage
First posted by the FDA 2021-02-17 Presentations affected 1 Manufacturer contact 800-796-9526 Rifampin, Injection, 600 mg (NDC 67457-445-60) Unavailable Demand increase for the drug
	Rocuronium Bromide Injection	Eugia US LLC	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 888-238-7880 Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10) Available Check wholesalers for inventory Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05) Available Check wholesalers for inventory
	Rocuronium Bromide Injection	Mylan Institutional, a Viatris Company	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 800-796-9526 Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05) Available Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10) Available
	Ropivacaine Hydrochloride Injection	Eugia US LLC	Anesthesia	2026-10-19	Currently in Shortage
First posted by the FDA 2018-03-23 Presentations affected 7 Manufacturer contact 888-238-7880 Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10) Available Check wholesalers for inventory Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20) Available Check wholesalers for inventory Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20) Unavailable Demand increase for the drug Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99) Available Check wholesalers for inventory Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20) Available Check wholesalers for inventory Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30) Available Check wholesalers for inventory Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20) Unavailable Demand increase for the drug
	Sterile Water Irrigant	B. Braun Medical Inc.	Gastroenterology Other Pediatric	2026-10-19	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 2 Manufacturer contact 800-227-2862 Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00) Available Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10) Available
	Technetium TC-99M Pyrophosphate Kit Injection	Sun Pharmaceutical Industries, Inc.	Medical Imaging	2026-10-19	Currently in Shortage
First posted by the FDA 2023-12-27 Presentations affected 2 Manufacturer contact 800-818-4555 CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1) Unavailable Other CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2) Unavailable Other
	Atropine Sulfate Injection	Accord Healthcare Inc.	Anesthesia Neurology Pediatric	2026-10-17	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 6 Manufacturer contact 866-941-7875, option 2 Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03) Unavailable Discontinuation of the manufacture of the drug Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90) Unavailable Discontinuation of the manufacture of the drug Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45) Available Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08) Unavailable Requirements related to complying with good manufacturing practices Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43) Unavailable Requirements related to complying with good manufacturing practices Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08) Unavailable Requirements related to complying with good manufacturing practices
	Azacitidine Injection	Accord Healthcare Inc.	Oncology	2026-10-17	Currently in Shortage
First posted by the FDA 2020-12-21 Presentations affected 1 Manufacturer contact 866-941-7875, option 2 Azacitidine, Injection, 100 mg (NDC 16729-306-10) Available
	Carboplatin Injection	Accord Healthcare Inc.	Oncology	2026-10-17	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 4 Manufacturer contact 866-941-7875, option 2 Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) Unavailable Demand increase for the drug Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) Unavailable Demand increase for the drug Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) Unavailable Demand increase for the drug Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) Unavailable Demand increase for the drug
	Clonazepam Tablet	Accord Healthcare Inc.	Neurology Pediatric Psychiatry	2026-10-17	Currently in Shortage
First posted by the FDA 2023-03-10 Presentations affected 6 Manufacturer contact 866-941-7875, option 2 Clonazepam, Tablet, .5 mg (NDC 16729-136-00) Available Clonazepam, Tablet, .5 mg (NDC 16729-136-16) Available Clonazepam, Tablet, 1 mg (NDC 16729-137-00) Available Clonazepam, Tablet, 1 mg (NDC 16729-137-16) Available Clonazepam, Tablet, 2 mg (NDC 16729-138-00) Available Clonazepam, Tablet, 2 mg (NDC 16729-138-16) Available
	Furosemide Injection	Accord Healthcare Inc.	Cardiovascular	2026-10-17	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 866-941-7875 Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08) Unavailable Requirements related to complying with good manufacturing practices Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43) Unavailable Requirements related to complying with good manufacturing practices Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43) Unavailable Requirements related to complying with good manufacturing practices
	Methotrexate Sodium Injection	Accord Healthcare Inc.	Oncology Rheumatology	2026-10-17	Currently in Shortage
First posted by the FDA 2023-03-13 Presentations affected 2 Manufacturer contact 866-941-7875, option 2 Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) Available Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) Unavailable Other
	Amino Acid Injection	Baxter Healthcare	Gastroenterology	2026-10-16	Currently in Shortage
First posted by the FDA 2020-12-08 Presentations affected 9 Manufacturer contact 888-229-0001 Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03) Available Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06) Available Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03) Available Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04) Available Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06) Available PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06) Available Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03) Unavailable Shortage of an inactive ingredient component Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04) Available Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06) Available
	Amino Acid Injection	Otsuka ICU Medical LLC	Gastroenterology	2026-10-16	Currently in Shortage
First posted by the FDA 2020-12-08 Presentations affected 4 Manufacturer contact 1-866-829-9025 or [email protected] Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05) Unavailable Shortage of an active ingredient Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03) Unavailable Shortage of an active ingredient
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Alvogen	Psychiatry	2026-10-16	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 5 Manufacturer contact 844-842-8672 and email: [email protected] Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01) Available
	Atropine Sulfate Injection	Amphastar Pharmaceuticals, Inc.	Anesthesia Neurology Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2020-01-01 Presentations affected 1 Manufacturer contact 800-423-4136 Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1) Available
	Clindamycin Phosphate Injection	Baxter Healthcare	Anti-Infective	2026-10-16	Currently in Shortage
First posted by the FDA 2023-03-21 Presentations affected 6 Manufacturer contact 888-229-0001 Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50) Available Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50) Available Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50) Available Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50) Available Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50) Limited Availability Other Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50) Available
	Clonazepam Tablet	Cheplapharm Arzneimittel GmbH	Neurology Pediatric Psychiatry	2026-10-16	Currently in Shortage
First posted by the FDA 2023-03-10 Presentations affected 3 Manufacturer contact [email protected] Klonopin, Tablet, .5 mg (NDC 61269-605-10) Available Marketed by H2-Pharma Klonopin, Tablet, 1 mg (NDC 61269-610-10) Available Marketed by H2-Pharma Klonopin, Tablet, 2 mg (NDC 61269-620-10) Unavailable Other
	Cromolyn Sodium Concentrate	Micro Labs LTD	Pulmonary/Allergy	2026-10-16	Currently in Shortage
First posted by the FDA 2023-11-03 Presentations affected 1 Manufacturer contact (908) 484-7410 Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52) Available
	Dexmedetomidine Hydrochloride Injection	Baxter Healthcare	Anesthesia	2026-10-16	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 4 Manufacturer contact 888-229-0001 Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24) Available Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24) Available Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12) Available Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12) Available
	Dextrose Monohydrate 10% Injection	Baxter Healthcare	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2022-03-01 Presentations affected 3 Manufacturer contact 888-229-0001 Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02) Available Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03) Available Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04) Available
	Dextrose Monohydrate 10% Injection	Otsuka ICU Medical LLC	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2022-03-01 Presentations affected 4 Manufacturer contact 1-866-829-9025 or [email protected] Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19) Unavailable Discontinuation of the manufacture of the drug
	Dextrose Monohydrate 5% Injection	Baxter Healthcare	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2022-02-14 Presentations affected 16 Manufacturer contact 888-229-0001 Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40) Available Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10) Available Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30) Available Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20) Available Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11) Available Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18) Available Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11) Unavailable Demand increase for the drug Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41) Available Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48) Unavailable Demand increase for the drug
	Dextrose Monohydrate 5% Injection	Otsuka ICU Medical LLC	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2022-02-14 Presentations affected 10 Manufacturer contact 1-866-829-9025 or [email protected] Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
	Dextrose Monohydrate 50% Injection	Amphastar Pharmaceuticals, Inc.	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2022-01-13 Presentations affected 1 Manufacturer contact 800-423-4136 Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1) Limited Availability Demand increase for the drug
	Dextrose Monohydrate 70% Injection	Baxter Healthcare	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2024-10-11 Presentations affected 1 Manufacturer contact 888-229-0001 Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06) Available
	Dextrose Monohydrate 70% Injection	Otsuka ICU Medical LLC	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2024-10-11 Presentations affected 2 Manufacturer contact 1-866-829-9025 or [email protected] DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19) Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
	Dobutamine Hydrochloride Injection	Baxter Healthcare	Cardiovascular Pediatric Renal	2026-10-16	Currently in Shortage
First posted by the FDA 2017-11-06 Presentations affected 3 Manufacturer contact 888-229-0001 Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02) Available Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02) Available Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02) Available
	Dopamine Hydrochloride Injection	Baxter Healthcare	Cardiovascular	2026-10-16	Currently in Shortage
First posted by the FDA 2017-11-06 Presentations affected 4 Manufacturer contact 888-229-0001 Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02) Available Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03) Available Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02) Available Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03) Available
	Furosemide Injection	Baxter Healthcare	Cardiovascular	2026-10-16	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 888-229-0001 Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25) Available Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25) Available Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25) Available
	Heparin Sodium Injection	Baxter Healthcare	Hematology	2026-10-16	Currently in Shortage
First posted by the FDA 2017-11-14 Presentations affected 2 Manufacturer contact 888-229-0001 Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03) Limited Availability Demand increase for the drug Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04) Available
	Ifosfamide Injection	Baxter Healthcare	Oncology Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2026-06-12 Presentations affected 4 Manufacturer contact 888-229-0001 IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01) Available IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01) Unavailable Requirements related to complying with good manufacturing practices Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01) Available Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02) Available
	Ketorolac Tromethamine Injection	Baxter Healthcare	Analgesia/Addiction	2026-10-16	Currently in Shortage
First posted by the FDA 2018-06-06 Presentations affected 2 Manufacturer contact 888-229-0001 Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10) Unavailable Demand increase for the drug Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25) Available
	Lidocaine Hydrochloride Injection	Amphastar Pharmaceuticals, Inc.	Anesthesia Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2012-02-22 Presentations affected 1 Manufacturer contact 800-423-4136 Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1) Available
	Lidocaine Hydrochloride Injection	Baxter Healthcare	Cardiovascular	2026-10-16	Currently in Shortage
First posted by the FDA 2017-10-25 Presentations affected 2 Manufacturer contact 888-229-0001 Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03) Available Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02) Available
	Lisdexamfetamine Dimesylate Capsule	Alvogen	Psychiatry	2026-10-16	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 844-842-8672 and email: [email protected] Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01) Available Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01) Available Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01) Available Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01) Available
	Lorazepam Injection	Amphastar Pharmaceuticals, Inc.	Neurology	2026-10-16	Currently in Shortage
First posted by the FDA 2018-05-03 Presentations affected 1 Manufacturer contact 800-423-4136 Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) Available
	Methylphenidate Film, Extended Release	Noven Pharmaceuticals, Inc.	Psychiatry	2026-10-16	Currently in Shortage
First posted by the FDA 2025-02-28 Presentations affected 4 Manufacturer contact 800-455-8070 Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65) Available Distributed by Padagis US LLC Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65) Available Distributed by Padagis US LLC Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65) Available Distributed by Padagis US LLC Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65) Available Distributed by Padagis US LLC
	Methylphenidate Hydrochloride Tablet, Extended Release	Trigen Laboratories, LLC	Psychiatry	2026-10-16	Currently in Shortage
First posted by the FDA 2023-07-26 Presentations affected 7 Manufacturer contact 800-541-4802 Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) Limited Availability Demand increase for the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) Limited Availability Demand increase for the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) Limited Availability Demand increase for the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) Limited Availability Demand increase for the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) Limited Availability Demand increase for the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) Limited Availability Demand increase for the drug Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) Limited Availability Demand increase for the drug
	Methylphenidate Hydrochloride Tablet, Extended Release	Vertical Pharmaceuticals, LLC	Psychiatry	2026-10-16	Currently in Shortage
First posted by the FDA 2023-07-26 Presentations affected 11 Manufacturer contact 800-541-4802 Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) Available Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) Available Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) Available Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) Available Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) Available Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) Available Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) Available Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) Available Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) Available Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) Available Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) Available
	Metronidazole Injection	Baxter Healthcare	Anti-Infective	2026-10-16	Currently in Shortage
First posted by the FDA 2022-01-13 Presentations affected 1 Manufacturer contact 888-229-0001 Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48) Available
	Morphine Sulfate Injection	Amphastar Pharmaceuticals, Inc.	Analgesia/Addiction	2026-10-16	Currently in Shortage
First posted by the FDA 2018-12-06 Presentations affected 1 Manufacturer contact 800-423-4136 Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1) Available
	Rocuronium Bromide Injection	Baxter Healthcare	Anesthesia	2026-10-16	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 888-229-0001 Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10) Available Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10) Available
	Sodium Bicarbonate Injection	Amphastar Pharmaceuticals, Inc.	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2017-03-01 Presentations affected 1 Manufacturer contact 800-423-4136 Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1) Limited Availability Demand increase for the drug
	Sodium Bicarbonate Injection	Long Grove Pharmaceuticals LLC	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2017-03-01 Presentations affected 1 Manufacturer contact 833-268-5559 Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3) Available
	Sterile Water Irrigant	Baxter Healthcare	Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 3 Manufacturer contact 888-229-0001 Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02) Available Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03) Available Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04) Limited Availability Other
	Sterile Water Irrigant	Otsuka ICU Medical LLC	Gastroenterology Other Pediatric	2026-10-16	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 4 Manufacturer contact 1-866-829-9025 or [email protected] Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03) Unavailable Discontinuation of the manufacture of the drug More from the FDA Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22) Unavailable Discontinuation of the manufacture of the drug More from the FDA Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09) Unavailable Discontinuation of the manufacture of the drug More from the FDA Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36) Unavailable Discontinuation of the manufacture of the drug More from the FDA
	Technetium TC-99M Pyrophosphate Kit Injection	Curium US LLC	Medical Imaging	2026-10-16	Currently in Shortage
First posted by the FDA 2023-12-27 Presentations affected 1 Manufacturer contact 888-744-1414 Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20) Limited Availability Shortage of an active ingredient
	Vigabatrin Tablet	Hikma Pharmaceuticals USA, Inc.	Neurology	2026-10-16	To Be Discontinued
First posted by the FDA 2026-10-16 Presentations affected 1 Manufacturer contact 800-631-2174 Vigabatrin, Tablet, 500 mg (NDC 0054-0652-25) The decision to discontinue this drug product was due to a business decision and not due to any reasons of safety or effectiveness.
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Elite Laboratories, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 7 Manufacturer contact 888-852-6657 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01) Available
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Lannett Company, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 7 Manufacturer contact 844-834-0530 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37) Available
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Oryza Pharmaceuticals Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 5 Manufacturer contact 855-257-0292 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01) Unavailable Shortage of an active ingredient
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Sunrise Pharmaceutical, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 7 Manufacturer contact 732-382-6085 Monday to Friday 9 am to 3:45 pm Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01) Available
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Teva Pharmaceuticals USA, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 14 Manufacturer contact 800-545-8800 Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01) Available Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01) Available Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01) Available Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01) Unavailable Other Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01) Available Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01) Available Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02) Limited Availability Other
	Atropine Sulfate Injection	American Regent, Inc.	Anesthesia Neurology Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 2 Manufacturer contact 800-645-1706 Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25) Available Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25) Available
	Atropine Sulfate Injection	Fresenius Kabi USA, LLC	Anesthesia Neurology Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 1 Manufacturer contact 888-386-1300 Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20) Unavailable Other
	Atropine Sulfate Injection	Medefil, Inc.	Anesthesia Neurology Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 1 Manufacturer contact 630-682-4600 Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91) Available
	Azacitidine Injection	Bristol Myers Squibb Co.	Oncology	2026-10-15	Currently in Shortage
First posted by the FDA 2020-12-18 Presentations affected 1 Manufacturer contact 1-888-423-5436 Vidaza, Injection, 100 mg (NDC 59572-102-01) Available
	Azacitidine Injection	Fresenius Kabi USA, LLC	Oncology	2026-10-15	Currently in Shortage
First posted by the FDA 2020-12-18 Presentations affected 1 Manufacturer contact 1-888-386-1300 Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39) Unavailable Discontinuation of the manufacture of the drug
	Azacitidine Injection	Teva Pharmaceuticals USA, Inc.	Oncology	2026-10-15	Currently in Shortage
First posted by the FDA 2020-12-22 Presentations affected 1 Manufacturer contact 800-545-8800 Azacitidine, Injection, 100 mg (NDC 68001-313-56) Unavailable Other
	Bupivacaine Hydrochloride Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 10 Manufacturer contact 888-386-1300 Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17) Available Check wholesalers for inventory Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31) Unavailable Demand increase for the drug Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37) Available Check wholesalers for inventory Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57) Available Check wholesalers for inventory Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17) Available Check wholesalers for inventory Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31) Unavailable Delay in shipping of the drug Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37) Available Check wholesalers for inventory Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57) Available Check wholesalers for inventory Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17) Available Check wholesalers for inventory Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37) Available Check wholesalers for inventory
	Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 8 Manufacturer contact 888-386-1300 Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57) Unavailable Demand increase for the drug Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17) Available Check wholesalers for inventory Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37) Available Check wholesaler for inventory Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17) Available Check wholesalers for inventory Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31) Unavailable Delay in shipping of the drug Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37) Available Check wholesalers for inventory Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57) Unavailable Demand increase for the drug Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37) Available Check wholesaler for inventory
	Carboplatin Injection	Fresenius Kabi USA, LLC	Oncology	2026-10-15	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 1 Manufacturer contact 888-386-1300 Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) Unavailable Delay in shipping of the drug
	Carboplatin Injection	Teva Pharmaceuticals USA, Inc.	Oncology	2026-10-15	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 4 Manufacturer contact 800-545-8800 Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) Limited Availability Other Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) Unavailable Other Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) Available Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) Limited Availability Other
	Conivaptan Hydrochloride Injection	Cumberland Pharmaceuticals Inc.	Cardiovascular	2026-10-15	Currently in Shortage
First posted by the FDA 2022-03-14 Presentations affected 1 Manufacturer contact 800-706-5575 Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10) Unavailable Delay in shipping of the drug
	Desmopressin Acetate Spray	Apotex Corp.	Hematology	2026-10-15	Currently in Shortage
First posted by the FDA 2021-03-12 Presentations affected 1 Manufacturer contact 800-706-5575 Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0) Limited Availability Delay in shipping of the drug
	Dexamethasone Sodium Phosphate Injection	Fresenius Kabi USA, LLC	Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Other Pulmonary/Allergy Rheumatology	2026-10-15	Currently in Shortage
First posted by the FDA 2019-02-08 Presentations affected 9 Manufacturer contact 888-386-1300 Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) Available Check wholesalers for inventory Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) Available Check wholesalers for inventory Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10) Unavailable Demand increase for the drug Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10) Unavailable Demand increase for the drug Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) Unavailable Demand increase for the drug Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05) Available Check wholesalers for inventory Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) Available Check wholesalers for inventory Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10) Available Checkwholesalers for inventory Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10) Available Check wholesalers for inventory
	Dexmedetomidine Hydrochloride Injection	Azurity Pharmaceuticals, Inc	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 4 Manufacturer contact 877-495-6856 Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10) Available Distributed by Wilshire Pharmaceuticals, Inc. Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10) Available Distributed by Civica Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08) Available Distributed by Wilshire Pharmaceuticals, Inc. Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08) Available Distributed by Civica
	Dexmedetomidine Hydrochloride Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 4 Manufacturer contact 888-386-1300 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02) Unavailable Demand increase for the drug Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00) Unavailable Delay in shipping of the drug Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20) Unavailable Other Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50) Unavailable Delay in shipping of the drug
	Dexmedetomidine Hydrochloride Injection	Par Health, USA LLC	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 3 Manufacturer contact 800-828-9393 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25) Unavailable Other Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20) Unavailable Other Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10) Unavailable Other
	Dextrose Monohydrate 10% Injection	Fresenius Kabi USA, LLC	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2022-03-01 Presentations affected 3 Manufacturer contact 888-386-1300 Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74) Available Check wholesalers for inventory Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75) Available Check wholesalers for inventory Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76) Available Check wholesalers for inventory
	Dextrose Monohydrate 5% Injection	Fresenius Kabi USA, LLC	Endocrinology/Metabolism Gastroenterology Other Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2022-02-14 Presentations affected 5 Manufacturer contact 888-386-1300 Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60) Available Check wholealers for inventory Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30) Available Check wholesalers for inventory Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20) Available Check wholesalers for inventory Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10) Available Check wholesalers for inventory Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50) Available Check wholesalers for inventory
	Epinephrine Bitartrate, Lidocaine Hydrochloride Injection	Fresenius Kabi USA, LLC	Anesthesia Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2016-10-14 Presentations affected 12 Manufacturer contact 888-386-1300 Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17) Available Check wholesalers for inventory Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37) Available Check wholesalers for inventory Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17) Available Check wholesalers for inventory Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37) Available Check wholesalers for inventory Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17) Available Check wholesalers for inventory Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27) Unavailable Other Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57) Unavailable Demand increase for the drug Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17) Unavailable Demand increase for the drug Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27) Available Check wholesalers for inventory Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57) Available Check wholesalers for inventory Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27) Available Check wholesalers for inventory Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57) Available Check wholesalers for inventory
	Fentanyl Citrate Injection	Fresenius Kabi USA, LLC	Analgesia/Addiction Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 6 Manufacturer contact 888-386-1300 Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01) Available Check wholesalers for inventory Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02) Available Check wholesalers for inventory Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05) Available Check wholesalers for inventory Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20) Available Check wholesalers for inventory Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50) Available Check wholesalers for inventory Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11) Available Check wholesalers for inventory
	Furosemide Injection	Avet Pharmaceuticals, Inc.	Cardiovascular	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 855-228-9470 Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41) Available Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42) Available Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44) Unavailable Other
	Furosemide Injection	Fresenius Kabi USA, LLC	Cardiovascular	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 888-386-1300 Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02) Available Check wholesalers for inventory Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04) Available Check wholesalers for inventory Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10) Available Check wholesalers for inventory
	Heparin Sodium Injection	Fresenius Kabi USA, LLC	Hematology	2026-10-15	Currently in Shortage
First posted by the FDA 2017-11-14 Presentations affected 2 Manufacturer contact 888-386-1300 Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10) Available Check wholesalers for inventory Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77) Unavailable Other
	Hydromorphone Hydrochloride Injection	Fresenius Kabi USA, LLC	Analgesia/Addiction	2026-10-15	Currently in Shortage
First posted by the FDA 2017-10-31 Presentations affected 10 Manufacturer contact 888-386-1300 Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11) Unavailable Other Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06) Unavailable Other Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11) Unavailable Other Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11) Unavailable Other Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25) Available Check wholesalers for inventory Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10) Available Check wholesalers for inventory Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15) Available Check wholesaler for inventory Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50) Available Check wholesalers for inventory Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25) Available Check wholesalers for inventory Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10) Available Check wholesalers for inventory
	Hydromorphone Hydrochloride Injection	Teva Pharmaceuticals USA, Inc.	Analgesia/Addiction	2026-10-15	Currently in Shortage
First posted by the FDA 2017-11-01 Presentations affected 3 Manufacturer contact 800-545-8800 Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01) Available Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03) Available Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03) Limited Availability Other
	Hydroxocobalamin Injection	Teva Pharmaceuticals USA, Inc.	Other	2026-10-15	Currently in Shortage
First posted by the FDA 2024-11-04 Presentations affected 1 Manufacturer contact 800-545-8800 Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30) Unavailable Other
	Ifosfamide Injection	Fresenius Kabi USA, LLC	Oncology Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2026-06-12 Presentations affected 1 Manufacturer contact 888-386-1300 Ifosfamide, Injection, 1 g/1 (NDC 63323-142-10) Limited Availability Demand increase for the drug
	Ketorolac Tromethamine Injection	Fresenius Kabi USA, LLC	Analgesia/Addiction	2026-10-15	Currently in Shortage
First posted by the FDA 2018-03-23 Presentations affected 6 Manufacturer contact 888-386-1300 Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01) Available Check wholesalers for inventory Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10) Unavailable Other Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01) Unavailable Delay in shipping of the drug Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02) Unavailable Delay in shipping of the drug Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10) Unavailable Other Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20) Unavailable Other
	Lidocaine Hydrochloride Injection	Fresenius Kabi USA, LLC	Anesthesia Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2012-02-22 Presentations affected 20 Manufacturer contact 888-386-1300 Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02) Available Check wholesalers for inventory Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02) Available Check wholesalers for inventory Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27) Available Check wholesalers for inventory Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57) Unavailable Demand increase for the drug Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27) Available Check wholesalers for inventory Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31) Unavailable Demand increase for the drug Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37) Available Check wholesalers for inventory Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57) Available Check wholesalers for inventory Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91) Unavailable Demand increase for the drug Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97) Unavailable Demand increase for the drug Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17) Available Check wholesalers for inventory Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27) Available Check wholesalers for inventory Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57) Unavailable Other Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07) Available Check wholesalers for inventory Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27) Available Check wholesalers for inventory Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97) Unavailable Demand increase for the drug Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57) Unavailable Demand increase for the drug Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57) Available Check wholesalers for inventory
	Lisdexamfetamine Dimesylate Capsule	Apotex Corp.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-11-01 Presentations affected 7 Manufacturer contact 800-706-5575 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1) Available Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1) Available Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1) Available Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1) Available
	Lisdexamfetamine Dimesylate Capsule	Elite Laboratories, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 888-852-6657 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01) Limited Availability Shortage of an active ingredient
	Lisdexamfetamine Dimesylate Capsule	Lannett Company, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 844-834-0530 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37) Limited Availability Other Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37) Available
	Lisdexamfetamine Dimesylate Capsule	Takeda Pharmaceuticals USA Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 877-TAKEDA-7 (1-877-825-3327) Vyvanse, Capsule, 10 mg (NDC 59417-101-10) Available Vyvanse, Capsule, 20 mg (NDC 59417-102-10) Available Vyvanse, Capsule, 30 mg (NDC 59417-103-10) Available Vyvanse, Capsule, 40 mg (NDC 59417-104-10) Available Vyvanse, Capsule, 50 mg (NDC 59417-105-10) Available Vyvanse, Capsule, 60 mg (NDC 59417-106-10) Available Vyvanse, Capsule, 70 mg (NDC 59417-107-10) Available
	Lisdexamfetamine Dimesylate Capsule	Teva Pharmaceuticals USA, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 800-545-8800 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01) Available Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01) Available Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01) Available Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01) Available
	Lisdexamfetamine Dimesylate Tablet, Chewable	Takeda Pharmaceuticals USA Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 6 Manufacturer contact 877-TAKEDA-7 (1-877-825-3327) Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01) Available Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01) Available Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01) Available Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01) Available Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01) Available Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01) Available
	Lorazepam Injection	Fresenius Kabi USA, LLC	Neurology	2026-10-15	Currently in Shortage
First posted by the FDA 2018-05-03 Presentations affected 1 Manufacturer contact 888-386-1300 Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02) Available Check wholesalers for inventory
	Methotrexate Sodium Injection	Fresenius Kabi USA, LLC	Oncology Rheumatology	2026-10-15	Currently in Shortage
First posted by the FDA 2023-03-13 Presentations affected 2 Manufacturer contact 888-386-1300 Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) Available Check wholesaler for inventory Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) Available Check wholesaler for inventory
	Methotrexate Sodium Injection	Teva Pharmaceuticals USA, Inc.	Oncology Rheumatology	2026-10-15	Currently in Shortage
First posted by the FDA 2023-03-13 Presentations affected 3 Manufacturer contact 800-545-8800 Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) Limited Availability Other Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) Unavailable Other Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) Limited Availability Other
	Methylphenidate Hydrochloride Tablet, Extended Release	Lannett Company, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-26 Presentations affected 4 Manufacturer contact 844-834-0530 Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) Available Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) Unavailable Other Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) Unavailable Other Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) Available
	Methylphenidate Hydrochloride Tablet, Extended Release	Teva Pharmaceuticals USA, Inc.	Psychiatry	2026-10-15	Currently in Shortage
First posted by the FDA 2023-07-26 Presentations affected 4 Manufacturer contact 800-545-8800 Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) Available Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) Limited Availability Other Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) Limited Availability Other Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) Available
	Methylprednisolone Acetate Injection	Par Health, USA LLC	Rheumatology	2026-10-15	Currently in Shortage
First posted by the FDA 2022-06-16 Presentations affected 1 Manufacturer contact 800-828-9393 Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01) Unavailable Other
	Midazolam Hydrochloride Injection	Avet Pharmaceuticals, Inc.	Anesthesia Neurology	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-02 Presentations affected 3 Manufacturer contact 855-228-9470 Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41) Available Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41) Available Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42) Available
	Midazolam Hydrochloride Injection	Fresenius Kabi USA, LLC	Anesthesia Neurology	2026-10-15	Currently in Shortage
First posted by the FDA 2020-04-02 Presentations affected 7 Manufacturer contact 888-386-1300 Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20) Unavailable Demand increase for the drug Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10) Unavailable Delay in shipping of the drug Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12) Available Check wholesalers for inventory Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25) Available Check wholesalers for inventory Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02) Available Check wholesalers for inventory Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10) Unavailable Demand increase for the drug Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25) Available Check wholesalers for inventory
	Morphine Sulfate Injection	Fresenius Kabi USA, LLC	Analgesia/Addiction	2026-10-15	Currently in Shortage
First posted by the FDA 2017-10-31 Presentations affected 6 Manufacturer contact 888-386-1300 Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01) Available Check wholesalers for inventory Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01) Available Check wholesalers for inventory Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11) Available Check wholesalers for inventory Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01) Unavailable Other Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11) Available Check wholesalers for inventory Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01) Unavailable Demand increase for the drug
	Propranolol Hydrochloride Injection	Fresenius Kabi USA, LLC	Cardiovascular	2026-10-15	Currently in Shortage
First posted by the FDA 2023-10-31 Presentations affected 1 Manufacturer contact 888-386-1300 Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01) Unavailable Delay in shipping of the drug
	Remifentanil Hydrochloride Injection	Fresenius Kabi USA, LLC	Analgesia/Addiction	2026-10-15	Currently in Shortage
First posted by the FDA 2022-06-28 Presentations affected 3 Manufacturer contact 888-386-1300 Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03) Unavailable Delay in shipping of the drug Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05) Available Check wholesalers for inventory Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10) Available Check wholesalers for inventory
	Rifampin Injection	Fresenius Kabi USA, LLC	Anti-Infective	2026-10-15	Currently in Shortage
First posted by the FDA 2021-02-17 Presentations affected 1 Manufacturer contact 888-386-1300 Rifampin, Injection, 600 mg (NDC 63323-351-20) Limited Availability Other
	Riluzole Oral Suspension	EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)	Neurology	2026-10-15	Currently in Shortage
First posted by the FDA 2024-01-26 Presentations affected 4 Manufacturer contact 610-937-6172 Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1) Available More from the FDA Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1) Available More from the FDA Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1) Available More from the FDA Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1) Unavailable Requirements related to complying with good manufacturing practices
	Rocuronium Bromide Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 5 Manufacturer contact 888-386-1300 Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05) Unavailable Delay in shipping of the drug Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10) Available Check wholesalers for inventory Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05) Unavailable Delay in shipping of the drug Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05) Unavailable Delay in shipping of the drug Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10) Unavailable Delay in shipping of the drug
	Ropivacaine Hydrochloride Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-10-15	Currently in Shortage
First posted by the FDA 2018-03-23 Presentations affected 22 Manufacturer contact 888-386-1300 Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10) Unavailable Delay in shipping of the drug Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11) Available Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20) Unavailable Delay in shipping of the drug Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21) Available Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10) Unavailable Demand increase for the drug Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13) Unavailable Other Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20) Unavailable Other Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23) Available Check wholesalers for inventory Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61) Unavailable Other Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63) Unavailable Other Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64) Available Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65) Available Check wholesalers for inventory Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10) Available Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20) Available Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00) Available Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20) Unavailable Delay in shipping of the drug Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23) Available Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31) Unavailable Delay in shipping of the drug Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35) Available Check wholesalers for inventory Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63) Available Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20) Unavailable Demand increase for the drug Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21) Available Check wholesalers for inventory
	Sodium Acetate Injection	Fresenius Kabi USA, LLC	Endocrinology/Metabolism Gastroenterology Pediatric Total Parenteral Nutrition	2026-10-15	Currently in Shortage
First posted by the FDA 2016-03-23 Presentations affected 1 Manufacturer contact 888-386-1300 Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00) Unavailable Other
	Sodium Acetate Injection	Milla Pharmaceuticals	Endocrinology/Metabolism Gastroenterology Pediatric Total Parenteral Nutrition	2026-10-15	Currently in Shortage
First posted by the FDA 2016-02-03 Presentations affected 4 Manufacturer contact 833-251-8463 Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10) Available Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10) Available Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10) Available Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10) Limited Availability Other
	Sodium Bicarbonate Injection	Exela Pharma Sciences, LLC	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2017-07-24 Presentations affected 3 Manufacturer contact 828-758-5474 ext. 154 Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4) Available Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5) Available Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4) Available
	Sodium Bicarbonate Injection	Fresenius Kabi USA, LLC	Endocrinology/Metabolism Gastroenterology Pediatric	2026-10-15	Currently in Shortage
First posted by the FDA 2017-07-24 Presentations affected 2 Manufacturer contact 888-386-1300 Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05) Available Check wholesalers for inventory. Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50) Available Check wholesalers for inventory
	Sterile Water Injection	Fresenius Kabi USA, LLC	Other	2026-10-15	Currently in Shortage
First posted by the FDA 2021-11-23 Presentations affected 4 Manufacturer contact 888-386-1300 Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10) Unavailable Demand increase for the drug Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20) Available Check wholesalers for inventory Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50) Available Check wholesalers for inventory Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76) Available Check wholesalers for inventory
	Sterile Water Injection	Medefil, Inc.	Other	2026-10-15	Currently in Shortage
First posted by the FDA 2021-11-23 Presentations affected 1 Manufacturer contact 630-682-4600 Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30) Available
	Streptozocin Powder, For Solution	Teva Pharmaceuticals USA, Inc.	Oncology	2026-10-15	Currently in Shortage
First posted by the FDA 2022-07-12 Presentations affected 1 Manufacturer contact 800-545-8800 Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01) Unavailable Other
	Valproate Sodium Injection	Fresenius Kabi USA, LLC	Neurology	2026-10-15	Currently in Shortage
First posted by the FDA 2020-12-30 Presentations affected 1 Manufacturer contact 888-386-1300 Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05) Unavailable Demand increase for the drug
	Atropine Sulfate Injection	Hikma Pharmaceuticals USA, Inc.	Anesthesia Neurology Pediatric	2026-10-14	Currently in Shortage
First posted by the FDA 2023-12-20 Presentations affected 1 Manufacturer contact 800-631-2174 Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10) Available
	Azacitidine Injection	Hikma Pharmaceuticals USA, Inc.	Oncology	2026-10-14	Currently in Shortage
First posted by the FDA 2020-12-18 Presentations affected 1 Manufacturer contact 1-800-631-2174 Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01) Unavailable Demand increase for the drug
	Cefotaxime Sodium Powder, for Solution	Hikma Pharmaceuticals USA, Inc.	Anti-Infective Pediatric	2026-10-14	Currently in Shortage
First posted by the FDA 2015-02-17 Presentations affected 4 Manufacturer contact 800-631-2174 Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25) Unavailable Demand increase for the drug Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01) Unavailable Demand increase for the drug Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25) Unavailable Demand increase for the drug Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10) Unavailable Demand increase for the drug
	Dexamethasone Sodium Phosphate Injection	Hikma Pharmaceuticals USA, Inc.	Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Other Pulmonary/Allergy Rheumatology	2026-10-14	Currently in Shortage
First posted by the FDA 2019-02-08 Presentations affected 3 Manufacturer contact 800-631-2174 Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) Available Product will be made available as it is released. Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) Unavailable Demand increase for the drug Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) Available Additional product will be made available as it is released.
	Dexmedetomidine Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Anesthesia	2026-10-14	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 1 Manufacturer contact 800-631-2174 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25) Available Additional product will be made available as it is released.
	Dexmedetomidine Hydrochloride Injection	Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)	Anesthesia	2026-10-14	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 1 Manufacturer contact See Related Information section below for customer service information Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02) Unavailable Discontinuation of the manufacture of the drug More from the FDA
	Dexmedetomidine Hydrochloride Injection	Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)	Anesthesia	2026-10-14	To Be Discontinued
First posted by the FDA 2026-10-14 Presentations affected 1 Manufacturer contact See Related Information section below for customer service information Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02) Discontinuation of the manufacture of the drug; Distributed by Avenacy; Contact information: 877-283-6229
	Dopamine Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Cardiovascular	2026-10-14	Currently in Shortage
First posted by the FDA 2017-11-06 Presentations affected 2 Manufacturer contact 800-631-2174 Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25) Unavailable Demand increase for the drug Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25) Unavailable Demand increase for the drug
	Etomidate Injection	Hikma Pharmaceuticals USA, Inc.	Anesthesia	2026-10-14	Currently in Shortage
First posted by the FDA 2022-10-05 Presentations affected 6 Manufacturer contact 800-631-2174 Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10) Available Novaplus label Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10) Available Novaplus label Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10) Available Additional product will be made available as it is released. Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10) Available Additional product will be made available as it is released. Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10) Available Distributed by Civica Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10) Available Distributed by Civica
	Everolimus Tablet	Par Health, USA LLC	Transplant	2026-10-14	To Be Discontinued
First posted by the FDA 2026-10-14 Presentations affected 4 Manufacturer contact 800-828-9393 Everolimus, Tablet, .25 mg (NDC 49884-158-02) A business decision was made to withdraw from sale. Everolimus, Tablet, .5 mg (NDC 49884-159-02) A business decision was made to withdraw from sale. Everolimus, Tablet, .75 mg (NDC 49884-160-02) A business decision was made to withdraw from sale. Everolimus, Tablet, 1 mg (NDC 49884-283-02) A business decision was made to withdraw from sale.
	Fentanyl Citrate Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction Pediatric	2026-10-14	Currently in Shortage
First posted by the FDA 2023-12-20 Presentations affected 8 Manufacturer contact 800-631-2174 Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25) Available Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25) Available Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25) Available Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01) Available Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25) Available Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released. Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10) Unavailable Other Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10) Unavailable Other Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05) Unavailable Other
	Furosemide Oral Solution	Hikma Pharmaceuticals USA, Inc.	Cardiovascular	2026-10-14	Currently in Shortage
First posted by the FDA 2026-03-31 Presentations affected 3 Manufacturer contact 800-631-2174 Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46) Available Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50) Limited Availability Shortage of an inactive ingredient component Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63) Available Shortage of an inactive ingredient component
	Hydromorphone Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction	2026-10-14	Currently in Shortage
First posted by the FDA 2017-11-01 Presentations affected 2 Manufacturer contact 800-631-2174 Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25) Available Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01) Unavailable Demand increase for the drug
	Ifosfamide Injection	Hikma Pharmaceuticals USA, Inc.	Oncology Pediatric	2026-10-14	Currently in Shortage
First posted by the FDA 2026-06-12 Presentations affected 2 Manufacturer contact 800-631-2174 Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01) Unavailable Demand increase for the drug Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01) Unavailable Demand increase for the drug
	Ketorolac Tromethamine Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction	2026-10-14	Currently in Shortage
First posted by the FDA 2018-06-06 Presentations affected 3 Manufacturer contact 800-631-2174 Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25) Unavailable Other Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25) Unavailable Other Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25) Unavailable Other
	Lidocaine Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Anesthesia	2026-10-14	Currently in Shortage
First posted by the FDA 2018-06-13 Presentations affected 4 Manufacturer contact 800-631-2174 Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10) Available Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10) Available Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25) Unavailable Demand increase for the drug Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
	Liraglutide Injection	Hikma Pharmaceuticals USA, Inc.	Endocrinology/Metabolism	2026-10-14	Currently in Shortage
First posted by the FDA 2023-07-18 Presentations affected 2 Manufacturer contact 800-631-2174 Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) Available Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) Available
	Lisdexamfetamine Dimesylate Capsule	Hikma Pharmaceuticals USA, Inc.	Psychiatry	2026-10-14	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 800-631-2174 Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25) Limited Availability Shortage of an active ingredient
	Lorazepam Injection	Hikma Pharmaceuticals USA, Inc.	Neurology	2026-10-14	Currently in Shortage
First posted by the FDA 2018-05-03 Presentations affected 8 Manufacturer contact 800-631-2174 Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10) Unavailable Other Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25) Limited Availability Demand increase for the drug Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10) Unavailable Other Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25) Limited Availability Demand increase for the drug Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25) Limited Availability Demand increase for the drug Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10) Unavailable Other Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25) Limited Availability Demand increase for the drug Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10) Unavailable Other
	Meperidine Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction	2026-10-14	Currently in Shortage
First posted by the FDA 2025-05-30 Presentations affected 3 Manufacturer contact 800-631-2174 Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
	Methotrexate Sodium Injection	Hikma Pharmaceuticals USA, Inc.	Oncology Rheumatology	2026-10-14	Currently in Shortage
First posted by the FDA 2023-03-13 Presentations affected 2 Manufacturer contact 800-631-2174 Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) Unavailable Demand increase for the drug Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) Unavailable Demand increase for the drug
	Midazolam Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Anesthesia Neurology	2026-10-14	Currently in Shortage
First posted by the FDA 2020-04-02 Presentations affected 5 Manufacturer contact 800-631-2174 Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
	Morphine Sulfate Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction	2026-10-14	Currently in Shortage
First posted by the FDA 2017-11-03 Presentations affected 7 Manufacturer contact 800-631-2174 Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01) Unavailable Demand increase for the drug Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
	Promethazine Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction Gastroenterology Pediatric Pulmonary/Allergy	2026-10-14	Currently in Shortage
First posted by the FDA 2023-11-21 Presentations affected 8 Manufacturer contact 800-631-2174 Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25) Unavailable Other Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25) Unavailable Other Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35) Unavailable Demand increase for the drug Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25) Unavailable Demand increase for the drug Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35) Available Additional lots are scheduled to be manufactured. Product will be made available as it is released.
	Propranolol Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Cardiovascular	2026-10-14	Currently in Shortage
First posted by the FDA 2023-10-31 Presentations affected 1 Manufacturer contact 800-631-2174 Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10) Unavailable Shortage of an active ingredient
	Remifentanil Hydrochloride Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction	2026-10-14	Currently in Shortage
First posted by the FDA 2022-06-28 Presentations affected 3 Manufacturer contact 800-631-2174 Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10) Unavailable Demand increase for the drug Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10) Unavailable Demand increase for the drug Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) Unavailable Demand increase for the drug
	Rocuronium Bromide Injection	Hikma Pharmaceuticals USA, Inc.	Anesthesia	2026-10-14	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 800-631-2174 Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10) Available Additional lots will be available. Product will be made available as it is released. Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10) Available Additional lots will be available. Product will be made available as it is released.
	Sodium Acetate Injection	Hikma Pharmaceuticals USA, Inc.	Endocrinology/Metabolism Gastroenterology Pediatric Total Parenteral Nutrition	2026-10-14	Currently in Shortage
First posted by the FDA 2016-02-03 Presentations affected 2 Manufacturer contact 800-631-2174 Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01) Available Additional lots will be available. Product will be made available as it is released. Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01) Available Additional lots will be available. Product will be made available as it is released.
	Sterile Water Injection	Hikma Pharmaceuticals USA, Inc.	Other	2026-10-14	Currently in Shortage
First posted by the FDA 2021-11-23 Presentations affected 1 Manufacturer contact 800-631-2174 Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10) Unavailable Demand increase for the drug
	Sufentanil Citrate Injection	Hikma Pharmaceuticals USA, Inc.	Analgesia/Addiction Pediatric	2026-10-14	Currently in Shortage
First posted by the FDA 2022-05-03 Presentations affected 3 Manufacturer contact 800-631-2174 Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01) Unavailable Other Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02) Unavailable Other Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05) Unavailable Other
	Valproate Sodium Injection	Hikma Pharmaceuticals USA, Inc.	Neurology	2026-10-14	Currently in Shortage
First posted by the FDA 2020-12-30 Presentations affected 1 Manufacturer contact 800-631-2174 Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10) Available Additional lots will be available. Product will be made available as it is released.
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Granules Pharmaceuticals Inc.	Psychiatry	2026-10-13	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 7 Manufacturer contact 877-770-3183 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01) Unavailable Shortage of an active ingredient
	Quinapril Hydrochloride Tablet	Lupin Pharmaceuticals, Inc.	Cardiovascular	2026-10-13	Currently in Shortage
First posted by the FDA 2023-01-19 Presentations affected 4 Manufacturer contact Lupin Pharmaceuticals, Inc. Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09) Unavailable Requirements related to complying with good manufacturing practices Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09) Unavailable Requirements related to complying with good manufacturing practices Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09) Unavailable Requirements related to complying with good manufacturing practices Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09) Unavailable Requirements related to complying with good manufacturing practices
	Rifampin Capsule	Lupin Pharmaceuticals, Inc.	Anti-Infective	2026-10-13	Currently in Shortage
First posted by the FDA 2021-12-22 Presentations affected 3 Manufacturer contact 866-587-4617 Rifampin, Capsule, 150 mg (NDC 68180-658-06) Available Rifampin, Capsule, 300 mg (NDC 68180-659-06) Available Rifampin, Capsule, 300 mg (NDC 68180-659-07) Available
	Carboplatin Injection	Hospira, Inc., a Pfizer Company	Oncology	2026-10-08	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 8 Manufacturer contact 844-646-4398 Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) Unavailable Other Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) Limited Availability Other Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) Unavailable Other Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) Limited Availability Demand increase for the drug Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) Limited Availability Demand increase for the drug Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) Unavailable Other Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) Limited Availability Other Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) Unavailable Other
	Clindamycin Phosphate Injection	Sagent Pharmaceuticals	Anti-Infective	2026-10-08	Currently in Shortage
First posted by the FDA 2023-03-21 Presentations affected 3 Manufacturer contact 866-625-1618 Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02) Limited Availability Discontinuation of the manufacture of the drug Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04) Unavailable Discontinuation of the manufacture of the drug Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06) Limited Availability Discontinuation of the manufacture of the drug
	Ketorolac Tromethamine Injection	Sagent Pharmaceuticals	Analgesia/Addiction	2026-10-08	Currently in Shortage
First posted by the FDA 2018-03-26 Presentations affected 3 Manufacturer contact 866-625-1618 Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01) Limited Availability Delay in shipping of the drug Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01) Available Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02) Available
	Lidocaine Hydrochloride Injection	Spectra Medical Devices, LLC	Anesthesia	2026-10-08	Currently in Shortage
First posted by the FDA 2018-06-14 Presentations affected 1 Manufacturer contact 978-657-0889 ext. 5231 Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1) Unavailable Other
	Methylprednisolone Acetate Injection	Sagent Pharmaceuticals	Rheumatology	2026-10-08	Currently in Shortage
First posted by the FDA 2021-12-15 Presentations affected 3 Manufacturer contact 866-625-1618 Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05) Available Shortage of an active ingredient Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10) Limited Availability Shortage of an active ingredient Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05) Limited Availability Shortage of an active ingredient
	Rocuronium Bromide Injection	Sagent Pharmaceuticals	Anesthesia	2026-10-08	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 1 Manufacturer contact 866-625-1618 Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05) Available
	Felodipine Tablet, Extended Release	Par Health, USA LLC	Cardiovascular	2026-10-07	To Be Discontinued
First posted by the FDA 2026-10-07 Presentations affected 4 Manufacturer contact (800) 828-9393 Felodipine, Tablet, Extended Release, 2.5 mg (NDC 0603-3581-21) Discontinuation in the manufacturing of the drug product Felodipine, Tablet, Extended Release, 2.5 mg (NDC 0603-3581-28) Discontinuation in the manufacturing of the drug product Felodipine, Tablet, Extended Release, 5 mg (NDC 0603-3582-21) Discontinuation in the manufacturing of the drug product Felodipine, Tablet, Extended Release, 5 mg (NDC 0603-3582-28) Discontinuation in the manufacturing of the drug product
	Felodipine Tablet, Film Coated, Extended Release	Par Health, USA LLC	Cardiovascular	2026-10-07	To Be Discontinued
First posted by the FDA 2026-10-07 Presentations affected 2 Manufacturer contact (800) 828-9393 Felodipine, Tablet, Film Coated, Extended Release, 10 mg (NDC 0603-3583-21) Discontinuation in the manufacturing of the drug product Felodipine, Tablet, Film Coated, Extended Release, 10 mg (NDC 0603-3583-28) Discontinuation in the manufacturing of the drug product
	Dexmedetomidine Hydrochloride Injection	Amneal Pharmaceuticals	Anesthesia	2026-10-06	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 4 Manufacturer contact 866-525-7270 Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8) Available Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7) Available Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1) Available Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1) Available
	Lisdexamfetamine Dimesylate Capsule	Amneal Pharmaceuticals	Psychiatry	2026-10-06	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 6 Manufacturer contact 866-525-7270 Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09) Available Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09) Available Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09) Available Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09) Available
	Methylprednisolone Acetate Injection	Amneal Pharmaceuticals	Rheumatology	2026-10-06	Currently in Shortage
First posted by the FDA 2021-12-15 Presentations affected 4 Manufacturer contact 866-525-7270 Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1) Limited Availability Other Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5) Available Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1) Available Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5) Available
	Metronidazole Injection	InfoRLife SA	Anti-Infective	2026-10-06	Currently in Shortage
First posted by the FDA 2022-01-13 Presentations affected 2 Manufacturer contact Sagent: 866-625-1618 Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24) Limited Availability Other Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82) Limited Availability Other
	Ropivacaine Hydrochloride Injection	InfoRLife SA	Anesthesia	2026-10-06	Currently in Shortage
First posted by the FDA 2018-03-27 Presentations affected 6 Manufacturer contact Sagent: 866-625-1618 Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66) Available Marketed by Sagent Pharmaceuticals Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67) Unavailable Other Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82) Available Marketed by Sagent Pharmaceuticals Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87) Available Marketed by Sagent Pharmaceuticals Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82) Available Marketed by Sagent Pharmaceuticals Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87) Available Marketed by Sagent Pharmaceuticals
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Epic Pharma, LLC	Psychiatry	2026-10-05	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 5 Manufacturer contact (718) 276-8600 ext. 3 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01) Limited Availability Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01) Limited Availability Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01) Limited Availability Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01) Limited Availability Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01) Limited Availability Shortage of an active ingredient
	Dexmedetomidine Hydrochloride Injection	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anesthesia	2026-10-05	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 3 Manufacturer contact See Related Information section below for customer service information Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95) Available Marketed by Sandoz Inc.; Customer service: 800-525-8747 Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95) Available Marketed by Sandoz Inc.; Customer service: 800-525-8747 Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95) Available Marketed by Sandoz Inc.; Customer service: 800-525-8747
	Lidocaine Hydrochloride Injection	Anthea Pharma	Anesthesia Pediatric	2026-10-05	Currently in Shortage
First posted by the FDA 2012-02-22 Presentations affected 6 Manufacturer contact Avenacy, LLC: 877-283-6229 Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05) Available Distributed by Avenacy, LLC Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10) Available Distributed by Avenacy, LLC Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02) Available Distributed by Avenacy, LLC Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20) Available Distributed by Avenacy, LLC Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30) Available Distributed by Avenacy, LLC Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50) Available Distributed by Avenacy, LLC
	Rifampin Capsule	Epic Pharma, LLC	Anti-Infective	2026-10-05	Currently in Shortage
First posted by the FDA 2021-12-22 Presentations affected 6 Manufacturer contact (718) 276-8600 ext. 3 Rifampin, Capsule, 150 mg (NDC 42806-801-01) Unavailable Discontinuation of the manufacture of the drug Rifampin, Capsule, 150 mg (NDC 42806-801-30) Available Rifampin, Capsule, 300 mg (NDC 42806-799-01) Unavailable Discontinuation of the manufacture of the drug Rifampin, Capsule, 300 mg (NDC 42806-799-05) Unavailable Discontinuation of the manufacture of the drug Rifampin, Capsule, 300 mg (NDC 42806-799-30) Unavailable Discontinuation of the manufacture of the drug Rifampin, Capsule, 300 mg (NDC 42806-799-60) Available
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	Aurobindo Pharma USA	Psychiatry	2026-10-02	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 6 Manufacturer contact (866) 850-2876 or [email protected] Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01) Unavailable Shortage of an active ingredient Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01) Unavailable Shortage of an active ingredient
	Clonazepam Tablet	Aurobindo Pharma USA	Neurology Pediatric Psychiatry	2026-10-02	Currently in Shortage
First posted by the FDA 2023-03-10 Presentations affected 6 Manufacturer contact 866-850-2876 Clonazepam, Tablet, .5 mg (NDC 59651-722-01) Available Clonazepam, Tablet, .5 mg (NDC 59651-722-99) Available Clonazepam, Tablet, 1 mg (NDC 59651-723-01) Available Clonazepam, Tablet, 1 mg (NDC 59651-723-99) Available Clonazepam, Tablet, 2 mg (NDC 59651-724-01) Available Clonazepam, Tablet, 2 mg (NDC 59651-724-05) Available
	Fluocinonide Ointment	Teva Pharmaceuticals USA, Inc.	Dermatology	2026-10-02	To Be Discontinued
First posted by the FDA 2026-10-02 Presentations affected 3 Manufacturer contact 800-545-8800 Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-15) Discontinuation of the manufacture of the drug Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-30) Discontinuation of the manufacture of the drug Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-92) Discontinuation of the manufacture of the drug
	Quinapril Hydrochloride Tablet	Aurobindo Pharma USA	Cardiovascular	2026-10-02	Currently in Shortage
First posted by the FDA 2023-01-19 Presentations affected 3 Manufacturer contact 866-850-2876 Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) Unavailable Discontinuation of the manufacture of the drug Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90) Unavailable Discontinuation of the manufacture of the drug Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90) Unavailable Discontinuation of the manufacture of the drug
	Quinapril Hydrochloride Tablet	Chartwell Molecular Holdings LLC	Cardiovascular	2026-10-02	Currently in Shortage
First posted by the FDA 2023-01-19 Presentations affected 4 Manufacturer contact 845-268-5000 x 510 or Chartwell Customer service at [email protected] Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90) Available Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90) Available Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90) Available Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60) Available
	Quinapril/Hydrochlorothiazide Tablet	Aurobindo Pharma USA	Cardiovascular	2026-10-02	Currently in Shortage
First posted by the FDA 2023-01-19 Presentations affected 3 Manufacturer contact 866-850-2876 Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90) Unavailable Discontinuation of the manufacture of the drug Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90) Unavailable Discontinuation of the manufacture of the drug Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90) Unavailable Discontinuation of the manufacture of the drug
	Quinapril/Hydrochlorothiazide Tablet	Chartwell Molecular Holdings LLC	Cardiovascular	2026-10-02	Currently in Shortage
First posted by the FDA 2023-01-19 Presentations affected 3 Manufacturer contact 845-268-5000 x 510 or Chartwell Customer service at [email protected] Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90) Available Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90) Available Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90) Available
	Dexmedetomidine Hydrochloride Injection	HQ Specialty Pharma	Anesthesia	2026-10-01	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 4 Manufacturer contact WG Critical Care 888-493-0861 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04) Available Marketed by WG Critical Care Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04) Available Marketed by WG Critical Care Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24) Available Marketed by WG Critical Care Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24) Available Marketed by WG Critical Care
	Midazolam Hydrochloride Injection	WG Critical Care	Anesthesia Neurology	2026-10-01	Currently in Shortage
First posted by the FDA 2020-04-02 Presentations affected 2 Manufacturer contact 888-493-0861 Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10) Available Please check wholesalers and distributors for inventory. Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10) Available Please check wholesalers and distributors for inventory.
	Bumetanide Injection	Fresenius Kabi USA, LLC	Cardiovascular	2026-09-30	Shortage Resolved
First posted by the FDA 2018-01-31 Presentations affected 2 Manufacturer contact 888-386-1300 Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04) Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)
	Bumetanide Injection	Hikma Pharmaceuticals USA, Inc.	Cardiovascular	2026-09-30	Shortage Resolved
First posted by the FDA 2018-01-31 Presentations affected 2 Manufacturer contact 800-631-2174 Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10) Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)
	Bumetanide Injection	MSN Laboratories Private Limited	Cardiovascular	2026-09-30	Shortage Resolved
First posted by the FDA 2017-12-13 Presentations affected 4 Manufacturer contact 855-668-2369; [email protected] Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07) Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07) Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01) Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)
	Bumetanide Injection	Mullan Pharmaceutical Inc.	Cardiovascular	2026-09-30	Shortage Resolved
First posted by the FDA 2017-12-13 Presentations affected 2 Manufacturer contact 800-673-9839 Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2) Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)
	Bumetanide Injection	Sagent Pharmaceuticals	Cardiovascular	2026-09-30	Shortage Resolved
First posted by the FDA 2018-01-31 Presentations affected 2 Manufacturer contact 866-625-1618 Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04) Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)
	Cromolyn Sodium Concentrate	Ailex Pharmaceuticals	Pulmonary/Allergy	2026-09-30	Currently in Shortage
First posted by the FDA 2023-11-03 Presentations affected 3 Manufacturer contact Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or [email protected] Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96) Limited Availability Other Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96) Limited Availability Other Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96) Available Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195
	Ivermectin Tablet	Merck Sharp & Dohme LLC	Anti-Infective	2026-09-29	To Be Discontinued
First posted by the FDA 2026-09-29 Presentations affected 1 Manufacturer contact 800-672-6372 STROMECTOL, Tablet, 3 mg (NDC 0006-0032-01) Product will be discontinued on 10/31/2026
	Liraglutide Injection	Novo Nordisk, Inc.	Endocrinology/Metabolism	2026-09-22	Currently in Shortage
First posted by the FDA 2023-07-18 Presentations affected 5 Manufacturer contact 833-493-4689 Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) Available Distributed by Teva Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) Available Distributed by Teva Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) Limited Availability Discontinuation of the manufacture of the drug More from the FDA Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) Limited Availability Delay in shipping of the drug Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) Limited Availability Delay in shipping of the drug
	Promethazine Hydrochloride Injection	XGen Pharmaceuticals DJB, Inc.	Analgesia/Addiction Gastroenterology Other Pulmonary/Allergy	2026-09-22	Currently in Shortage
First posted by the FDA 2023-11-21 Presentations affected 2 Manufacturer contact 866-390-4411 Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3) Available Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6) Unvailable Demand increase for the drug
	Rocuronium Bromide Injection	XGen Pharmaceuticals DJB, Inc.	Anesthesia	2026-09-22	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 866-390-4411 Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6) Available Tamarang is the application holder and X-Gen is the distributor/labeler Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2) Available Tamarang is the application holder and X-Gen is the distributor/labeler
	Arsenic Trioxide Injection	Fresenius Kabi USA, LLC	Oncology	2026-09-21	To Be Discontinued
First posted by the FDA 2026-09-21 Presentations affected 1 Manufacturer contact 888-386-1300 Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 63323-637-10) Discontinuation of the manufacture of the drug
	Bupivacaine Hydrochloride Injection	ONESOURCE SPECIALTY PTE LTD	Anesthesia	2026-09-18	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 1 Manufacturer contact 888-217-8103 Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL 5mg / 1mL (NDC 72266-263-10) Available Distributed by Fosun Pharma USA Inc.
	Rifampin Injection	Sanofi-Aventis U.S. LLC	Anti-Infective	2026-09-18	Currently in Shortage
First posted by the FDA 2021-02-17 Presentations affected 1 Manufacturer contact 800-633-1610 Rifadin, Injection, 600 mg (NDC 0068-0597-01) Unavailable Discontinuation of the manufacture of the drug More from the FDA
	Rivaroxaban For Suspension	Janssen Pharmaceuticals	Hematology	2026-09-18	To Be Discontinued
First posted by the FDA 2026-09-18 Presentations affected 1 Manufacturer contact 800-526-7736 Xarelto, For Suspension, 155 mg (NDC 50458-575-01) Business Decision
	Rivastigmine Film, Extended Release	Mylan Pharmaceuticals Inc., a Viatris Company	Neurology	2026-09-18	To Be Discontinued
First posted by the FDA 2026-09-18 Presentations affected 1 Manufacturer contact 800-796-9526 Rivastigmine, Film, Extended Release, 4.6 mg/24 h (NDC 0378-9070-93) Discontinuation of the manufacture of the drug.
	Lisdexamfetamine Dimesylate Tablet, Chewable	Novadoz Pharmaceuticals LLC	Psychiatry	2026-09-16	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 6 Manufacturer contact (855) 668-2369; [email protected] Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91) Available Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91) Available
	Melphalan Hydrochloride Injection	Fresenius Kabi USA, LLC	Oncology	2026-09-16	To Be Discontinued
First posted by the FDA 2026-09-16 Presentations affected 1 Manufacturer contact 888-386-1300 Melphalan Hydrochloride, Injection, Kit (NDC 63323-760-20) Discontinuation of the manufacture of the drug
	Mesalamine Capsule, Extended Release	Takeda Pharmaceuticals USA Inc.	Gastroenterology	2026-09-16	To Be Discontinued
First posted by the FDA 2026-09-16 Presentations affected 2 Manufacturer contact 877 825 3327 Pentasa, Capsule, Extended Release, 250 mg (NDC 54092-189-81) Product is anticipated to be available until December 31, 2027 Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12) Product is anticipated to be available until December 31, 2027
	Streptozocin Powder, For Solution	ESTEVE PHARMACEUTICALS, S.A.	Oncology	2026-09-16	Currently in Shortage
First posted by the FDA 2022-07-12 Presentations affected 1 Manufacturer contact [email protected] Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01) Available More from the FDA
	Dexmedetomidine Hydrochloride Injection	Accord Healthcare Inc.	Anesthesia	2026-09-15	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 2 Manufacturer contact 866-941-7875, option 2 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93) Unavailable Discontinuation of the manufacture of the drug More from the FDA Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93) Unavailable Discontinuation of the manufacture of the drug
	Flurazepam Hydrochloride Capsule	Chartwell Molecular Holdings LLC	Neurology Oncology Other	2026-09-15	Currently in Shortage
First posted by the FDA 2022-08-03 Presentations affected 4 Manufacturer contact 845-268-5000 Ext. 510 Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30) Available Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90) Available Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30) Available Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90) Available
	Morphine Sulfate Injection	Piramal Critical Care Inc.	Analgesia/Addiction	2026-09-15	Currently in Shortage
First posted by the FDA 2017-10-31 Presentations affected 2 Manufacturer contact 800-414-1901 Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02) Available Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02) Available
	Penicillin G Benzathine Injection	Laboratorios Atral	Anti-Infective	2026-09-15	Currently in Shortage
First posted by the FDA 2023-04-26 Presentations affected 1 Manufacturer contact Mark Cuban Cost Plus Drug Company: 682-428-8081 Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01) Available More from the FDA
	Rocuronium Bromide Injection	Piramal Critical Care Inc.	Anesthesia	2026-09-15	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 800-414-1901 Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41) Limited Availability Demand increase for the drug Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41) Available
	Triamcinolone Hexacetonide Injection	Medexus	Rheumatology	2026-09-15	Currently in Shortage
First posted by the FDA 2021-05-04 Presentations affected 1 Manufacturer contact 1-855-336-3322 Option 9 Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01) Available More from the FDA
	Atropine Sulfate Injection	Somerset Therapeutics, LLC	Anesthesia Neurology Pediatric	2026-09-11	Currently in Shortage
First posted by the FDA 2012-01-01 Presentations affected 3 Manufacturer contact 732-554-1037 Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10) Available Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25) Available Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25) Available
	Bupivacaine Hydrochloride Injection	Somerset Therapeutics, LLC	Anesthesia	2026-09-11	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 6 Manufacturer contact 732-554-1037 Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01) Available Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10) Available Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25) Available Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01) Available Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10) Available Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25) Available
	Cisatracurium Besylate Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction	2026-09-11	To Be Discontinued
First posted by the FDA 2026-05-06 Presentations affected 3 Manufacturer contact 844-646-4398 Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02) Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01) Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01) Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
	Dexamethasone Sodium Phosphate Injection	Somerset Therapeutics, LLC	Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Other Pulmonary/Allergy Rheumatology	2026-09-11	Currently in Shortage
First posted by the FDA 2019-02-08 Presentations affected 2 Manufacturer contact 732-554-1019 Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25) Available Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10) Available
	Dexmedetomidine Hydrochloride Injection	Somerset Therapeutics, LLC	Anesthesia	2026-09-11	Currently in Shortage
First posted by the FDA 2020-04-10 Presentations affected 2 Manufacturer contact 732-554-1037 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04) Available Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04) Available
	Micafungin Sodium Injection	Par Health, USA LLC	Anti-Infective	2026-09-11	To Be Discontinued
First posted by the FDA 2026-09-11 Presentations affected 2 Manufacturer contact 800-828-9393 Micafungin Sodium, Injection, 10 mg/1 mL (NDC 42023-229-10) A business decision was made to discontinue manufacture of the drug. Micafungin Sodium, Injection, 20 mg/1 mL (NDC 42023-230-10) A business decision was made to discontinue manufacture of the drug.
	Ropivacaine Hydrochloride Injection	Somerset Therapeutics, LLC	Anesthesia	2026-09-11	Currently in Shortage
First posted by the FDA 2018-03-23 Presentations affected 10 Manufacturer contact 732-554-1037 Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10) Available Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25) Available Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10) Available Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25) Available Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10) Available Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25) Available Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25) Available Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01) Available Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10) Available Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25) Available
	Sodium Acetate Injection	Somerset Therapeutics, LLC	Endocrinology/Metabolism Gastroenterology Pediatric Total Parenteral Nutrition	2026-09-11	Currently in Shortage
First posted by the FDA 2016-02-03 Presentations affected 2 Manufacturer contact 732-554-1037 Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25) Available Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20) Available
	Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution	Fresenius Medical Care North America	Renal	2026-09-10	To Be Discontinued
First posted by the FDA 2026-09-10 Presentations affected 1 Manufacturer contact 800-323-5188 DELFLEX, Solution, 18.4 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 46163-212-95) A business decision was made to discontinue manufacture of the drug.
	Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection	Merck Sharp & Dohme LLC	Anti-Infective	2026-09-09	To Be Discontinued
First posted by the FDA 2026-09-09 Presentations affected 1 Manufacturer contact 800-672-6372 RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) To be discontinued on or near late September 2026.
	Ifosfamide Injection	SteriMax, Inc.	Oncology Pediatric	2026-09-08	Currently in Shortage
First posted by the FDA 2026-06-12 Presentations affected 1 Manufacturer contact 877-373-4657 Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02) Available To place an order, please contact GlobalRX at [email protected] or (919) 245-8418 More from the FDA
	Clonazepam Tablet	Prinston Pharmaceutical, Inc.	Neurology Pediatric Psychiatry	2026-09-02	Currently in Shortage
First posted by the FDA 2023-03-10 Presentations affected 8 Manufacturer contact For orders, Solco Healthcare 866-931-9829 Clonazepam, Tablet, .5 mg (NDC 43547-406-10) Available Marketed by Solco Healthcare Clonazepam, Tablet, .5 mg (NDC 43547-406-11) Available Marketed by Solco Healthcare Clonazepam, Tablet, .5 mg (NDC 43547-406-50) Available Marketed by Solco Healthcare Clonazepam, Tablet, 1 mg (NDC 43547-407-10) Available Marketed by Solco Healthcare Clonazepam, Tablet, 1 mg (NDC 43547-407-11) Available Marketed by Solco Healthcare Clonazepam, Tablet, 1 mg (NDC 43547-407-50) Available Marketed by Solco Healthcare Clonazepam, Tablet, 2 mg (NDC 43547-408-10) Available Marketed by Solco Healthcare Clonazepam, Tablet, 2 mg (NDC 43547-408-50) Available Marketed by Solco Healthcare
	Carboplatin Injection	Avyxa Pharma, LLC	Oncology	2026-09-01	Currently in Shortage
First posted by the FDA 2023-04-28 Presentations affected 2 Manufacturer contact 877-595-7337; [email protected] Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) Available Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) Available
	Cromolyn Sodium Concentrate	Rising Pharma Holdings, Inc.	Pulmonary/Allergy	2026-09-01	Currently in Shortage
First posted by the FDA 2023-11-03 Presentations affected 1 Manufacturer contact (201) 961-9000 or [email protected] Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96) Available
	Echothiophate Iodide Ophthalmic Solution	Fera Pharmaceuticals	Ophthalmology	2026-09-01	Currently in Shortage
First posted by the FDA 2019-09-24 Presentations affected 1 Manufacturer contact 516-277-1449 Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05) Available Other
	Flurazepam Hydrochloride Capsule	Rising Pharma Holdings, Inc.	Neurology Other	2026-09-01	Currently in Shortage
First posted by the FDA 2022-08-03 Presentations affected 2 Manufacturer contact 1-844-874-7464 Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01) Unavailable Regulatory delay Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01) Unavailable Regulatory delay
	Glycerol Phenylbutyrate Oral Liquid	Amgen Inc.	Inborn Errors	2026-09-01	To Be Discontinued
First posted by the FDA 2026-09-01 Presentations affected 2 Manufacturer contact 800-772-6436 RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-06) Discontinuation in the manufacturing of the drug product RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-07) Discontinuation in the manufacturing of the drug product
	Insulin Glargine-aglr Injection	Eli Lilly and Co.	Endocrinology/Metabolism	2026-09-01	To Be Discontinued
First posted by the FDA 2026-09-01 Presentations affected 1 Manufacturer contact 800-545-5979 Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05) A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
	Insulin Lispro Injection	Eli Lilly and Co.	Endocrinology/Metabolism	2026-09-01	To Be Discontinued
First posted by the FDA 2025-10-24 Presentations affected 2 Manufacturer contact 800-545-5979 Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05) A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance. Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05) A business decision was made to discontinue manufacture of the drug.
	Insulin Lispro Protamine and Insulin Lispro Injection	Eli Lilly and Co.	Endocrinology/Metabolism	2026-09-01	To Be Discontinued
First posted by the FDA 2026-09-01 Presentations affected 1 Manufacturer contact 800-545-5979 Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05) A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
	Medroxyprogesterone Acetate Tablet	Pfizer Inc.	Urology	2026-08-31	To Be Discontinued
First posted by the FDA 2026-08-31 Presentations affected 2 Manufacturer contact 800-533-4535 PROVERA, Tablet, 10 mg (NDC 0009-0051-01) Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026. PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01) Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.
	Metoprolol Succinate Tablet, Extended Release	Teva Pharmaceuticals USA, Inc.	Cardiovascular	2026-08-31	To Be Discontinued
First posted by the FDA 2026-08-31 Presentations affected 7 Manufacturer contact 800-545-8800 Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-11) A business decision was made to discontinue manufacture of the drug. Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-96) A business decision was made to discontinue manufacture of the drug. Metoprolol Succinate, Tablet, Extended Release, 200 mg (NDC 45963-678-11) A business decision was made to discontinue manufacture of the drug. Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-11) A business decision was made to discontinue manufacture of the drug. Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-96) A business decision was made to discontinue manufacture of the drug. Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-11) A business decision was made to discontinue manufacture of the drug. Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-96) A business decision was made to discontinue manufacture of the drug.
	Palovarotene Capsule	Ipsen Biopharmaceuticals, Inc.	Musculoskeletal	2026-08-31	To Be Discontinued
First posted by the FDA 2026-08-31 Presentations affected 1 Manufacturer contact (855)-463-5127 SOHONOS, Capsule, 2.5 mg (NDC 15054-0025-1) Discontinuation of the manufacture of the drug
	Potassium Chloride, Sodium Chloride, Calcium Chloride, and Magnesium Chloride Injection, Solution	Fresenius Kabi USA, LLC	Cardiovascular	2026-08-31	To Be Discontinued
First posted by the FDA 2026-08-31 Presentations affected 1 Manufacturer contact 888-386-1300 Cardioplegic Solution, Injection, Solution, 17.6 mg/100 mL; 325.3 mg/100 mL; 119.3 mg/100 mL; 643 mg/100 mL (NDC 65219-258-10) Discontinuation of the manufacture of the drug
	Albuterol Sulfate Solution	Nephron Pharmaceuticals Corporation	Pediatric Pulmonary/Allergy	2026-08-27	Shortage Resolved
First posted by the FDA 2022-10-25 Presentations affected 1 Manufacturer contact 800-443-4313 Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)
	Albuterol Sulfate Solution	Rising Pharma Holdings, Inc.	Pediatric Pulmonary/Allergy	2026-08-27	Shortage Resolved
First posted by the FDA 2022-10-25 Presentations affected 1 Manufacturer contact 201-961-9000 Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)
	Albuterol Sulfate Solution	Ritedose Pharmaceuticals, LLC	Pediatric Pulmonary/Allergy	2026-08-27	Shortage Resolved
First posted by the FDA 2022-10-25 Presentations affected 1 Manufacturer contact 803-806-3300 Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)
	Azacitidine Injection	Meitheal Pharmaceuticals, Inc.	Oncology	2026-08-27	Currently in Shortage
First posted by the FDA 2020-12-18 Presentations affected 1 Manufacturer contact 844-824-8426 Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30) Available
	Dexmedetomidine Hydrochloride Injection	Meitheal Pharmaceuticals, Inc.	Anesthesia	2026-08-27	Currently in Shortage
First posted by the FDA 2021-04-10 Presentations affected 1 Manufacturer contact 844-824-8426 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03) Available
	Furosemide Injection	Meitheal Pharmaceuticals, Inc.	Cardiovascular	2026-08-27	Currently in Shortage
First posted by the FDA 2020-04-07 Presentations affected 3 Manufacturer contact 844-824-8426 Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05) Available Check wholesalers for inventory Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11) Available Check wholesalers for inventory Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03) Available Check wholesalers for inventory
	Liraglutide Injection	Meitheal Pharmaceuticals, Inc.	Endocrinology/Metabolism	2026-08-27	Currently in Shortage
First posted by the FDA 2023-07-18 Presentations affected 2 Manufacturer contact 844-824-8426 Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) Available Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) Available
	Peginterferon alfa-2a Injection	pharmaand GmbH (pharma&)	Antiviral	2026-08-27	Shortage Resolved
First posted by the FDA 2025-01-24 Presentations affected 2 Manufacturer contact 800-506-8501, email: [email protected] Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4) Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)
	Rocuronium Bromide Injection	Meitheal Pharmaceuticals, Inc.	Anesthesia	2026-08-27	Currently in Shortage
First posted by the FDA 2023-02-15 Presentations affected 2 Manufacturer contact 844-824-8426 Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06) Available Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11) Available
	Liraglutide Injection	Novo Nordisk, Inc.	Endocrinology/Metabolism	2026-08-25	To Be Discontinued
First posted by the FDA 2026-08-25 Presentations affected 1 Manufacturer contact 833-493-4689 Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
	Mesalamine Capsule, Extended Release	Mylan Pharmaceuticals Inc., a Viatris Company	Gastroenterology	2026-08-25	To Be Discontinued
First posted by the FDA 2026-08-25 Presentations affected 1 Manufacturer contact 800-796-9526 Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78) Discontinuation of the manufacture of the drug
	Disopyramide Phosphate Capsule, Extended Release	Pfizer Inc.	Cardiovascular	2026-08-24	To Be Discontinued
First posted by the FDA 2026-08-24 Presentations affected 2 Manufacturer contact 800-533-4535 Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31) Discontinuation of the manufacture of the drug Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31) Discontinuation of the manufacture of the drug
	Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet	SpecGx LLC	Psychiatry	2026-08-20	Currently in Shortage
First posted by the FDA 2022-10-12 Presentations affected 6 Manufacturer contact 800-325-8888 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01) Limited Availability Demand increase for the drug Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01) Limited Availability Demand increase for the drug Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01) Available Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01) Limited Availability Demand increase for the drug
	Lisdexamfetamine Dimesylate Capsule	SpecGx LLC	Psychiatry	2026-08-20	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 800-325-8888 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01) Available Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01) Available Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01) Available Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01) Available Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01) Available
	Fulvestrant Injection	Fresenius Kabi USA, LLC	Oncology	2026-08-14	To Be Discontinued
First posted by the FDA 2026-08-14 Presentations affected 1 Manufacturer contact 888-386-1300 Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05) Discontinuation of the manufacture of the drug
	Diclofenac Sodium Tablet, Delayed Release	Teva Pharmaceuticals USA, Inc.	Musculoskeletal Rheumatology	2026-08-13	To Be Discontinued
First posted by the FDA 2026-08-13 Presentations affected 6 Manufacturer contact 800-545-8800 Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-06) A business decision was made to discontinue manufacture of the drug. Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-11) A business decision was made to discontinue manufacture of the drug. Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-96) A business decision was made to discontinue manufacture of the drug. Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-06) A business decision was made to discontinue manufacture of the drug. Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-11) A business decision was made to discontinue manufacture of the drug. Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-96) A business decision was made to discontinue manufacture of the drug.
	Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution	Salix Pharmaceuticals, a division of Bausch Health US, LLC	Gastroenterology	2026-08-13	To Be Discontinued
First posted by the FDA 2026-08-13 Presentations affected 1 Manufacturer contact 800-321-4576 Plenvu, Oral Solution, KIT (NDC 65649-400-01) A business decision was made to discontinue manufacture of the drug.
	Glyburide Tablet	Sanofi-Aventis U.S. LLC	Endocrinology/Metabolism	2026-08-10	To Be Discontinued
First posted by the FDA 2026-08-10 Presentations affected 4 Manufacturer contact 800-633-1610 Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53) A business decision was made to discontinue manufacture of the drug. Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01) A business decision was made to discontinue manufacture of the drug. Diabeta, Tablet, 5 mg (NDC 0093-9364-01) A business decision was made to discontinue manufacture of the drug. Diabeta, Tablet, 5 mg (NDC 0093-9364-10) A business decision was made to discontinue manufacture of the drug.
	Isocarboxazid Tablet	Lifsa Drugs LLC	Psychiatry	2026-08-06	Currently in Shortage
First posted by the FDA 2026-04-16 Presentations affected 1 Manufacturer contact 833.627.0070 Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01) Limited Availability Other
	Rifapentine Tablet, Film Coated	Sanofi-Aventis U.S. LLC	Anti-Infective	2026-08-06	Shortage Resolved
First posted by the FDA 2020-03-25 Presentations affected 1 Manufacturer contact 800-633-1610 Option 7 Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)
	Sterile Water Injection	Nephron Pharmaceuticals Corporation	Other	2026-08-04	Currently in Shortage
First posted by the FDA 2021-11-23 Presentations affected 1 Manufacturer contact 800-443-4313 Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01) Limited Availability Other
	Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution	Vantive US Healthcare LLC	Renal	2026-08-03	To Be Discontinued
First posted by the FDA 2026-08-03 Presentations affected 18 Manufacturer contact 800-284-4060 DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0409-07) A business decision was made to discontinue manufacture of the drug. DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0424-51) A business decision was made to discontinue manufacture of the drug. DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0430-51) A business decision was made to discontinue manufacture of the drug. DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0457-05) A business decision was made to discontinue manufacture of the drug. DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0433-51) A business decision was made to discontinue manufacture of the drug. DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0459-05) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-06) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-07) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-52) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-53) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-06) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-07) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-52) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-53) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-06) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-07) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-52) A business decision was made to discontinue manufacture of the drug. DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-53) A business decision was made to discontinue manufacture of the drug.
	Triamcinolone Acetonide Injection	Harrow Eye, LLC	Ophthalmology	2026-07-31	Shortage Resolved
First posted by the FDA 2021-09-27 Presentations affected 1 Manufacturer contact (615) 733-4734 Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)
	Bupivacaine Hydrochloride Injection	Huons Co., Ltd	Anesthesia	2026-07-30	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 1 Manufacturer contact +82-2-854-4700 or via email [email protected] Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2) Unavailable Demand increase for the drug
	Doxycycline Hyclate Tablet, Delayed Release	Teva Pharmaceuticals USA, Inc.	Anti-Infective	2026-07-30	To Be Discontinued
First posted by the FDA 2026-07-30 Presentations affected 2 Manufacturer contact 800-545-8800 Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60) Discontinuation of the manufacture of the drug Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22) Discontinuation of the manufacture of the drug
	Glycopyrrolate Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-07-30	To Be Discontinued
First posted by the FDA 2026-07-30 Presentations affected 4 Manufacturer contact 888-386-1300 Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01) Discontinuation of the manufacture of the drug Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01) Discontinuation of the manufacture of the drug Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02) Discontinuation of the manufacture of the drug Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05) Discontinuation of the manufacture of the drug
	Lidocaine Hydrochloride Injection	Huons Co., Ltd. (South Korea)	Anesthesia	2026-07-30	Currently in Shortage
First posted by the FDA 2018-07-14 Presentations affected 1 Manufacturer contact [email protected] Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2) Unavailable Demand increase for the drug
	Fluticasone Propionate and Salmeterol Xinafoate Aerosol, Metered	GlaxoSmithKline	Pulmonary/Allergy	2026-07-27	To Be Discontinued
First posted by the FDA 2026-07-27 Presentations affected 3 Manufacturer contact 888-825-5249 Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22) The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available. Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22) The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available. Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22) The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
	Lopinavir and Ritonavir Oral Solution	AbbVie Inc.	Antiviral	2026-07-24	To Be Discontinued
First posted by the FDA 2026-07-24 Presentations affected 1 Manufacturer contact 800-633-9110 Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46) Discontinuation of the manufacture of the drug
	Lopinavir and Ritonavir Tablet	AbbVie Inc.	Antiviral	2026-07-24	To Be Discontinued
First posted by the FDA 2026-07-24 Presentations affected 4 Manufacturer contact 800-633-9110 Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60) Discontinuation of the manufacture of the drug Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60) Discontinuation of the manufacture of the drug Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12) Discontinuation of the manufacture of the drug Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22) Discontinuation of the manufacture of the drug
	Ritonavir Oral Powder	AbbVie Inc.	Antiviral	2026-07-24	To Be Discontinued
First posted by the FDA 2026-07-24 Presentations affected 1 Manufacturer contact 800-633-9110 Norvir, Oral Powder, 100 mg (NDC 0074-3399-30) Discontinuation of the manufacture of the drug
	Ritonavir Tablet	AbbVie Inc.	Antiviral	2026-07-24	To Be Discontinued
First posted by the FDA 2026-07-24 Presentations affected 1 Manufacturer contact 800-633-9110 Norvir, Tablet, 100 mg (NDC 0074-2340-30) Discontinuation of the manufacture of the drug
	Aspirin Suppository	Padagis US LLC	Analgesia/Addiction Cardiovascular	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 1 Manufacturer contact (800) 775-2054 Aspirin, Suppository, 300 mg (NDC 0574-7034-12) Discontinuation of the manufacture of the drug
	Belladonna and Opium Suppository	Padagis US LLC	Analgesia/Addiction	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 4 Manufacturer contact (800) 775-2054 Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-04) Discontinuation of the manufacture of the drug Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-12) Discontinuation of the manufacture of the drug Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04) Discontinuation of the manufacture of the drug Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12) Discontinuation of the manufacture of the drug
	Bendamustine Hydrochloride Injection, Solution	Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)	Oncology	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 1 Manufacturer contact (610) 344-0200 Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08) A business decision has been made to discontinue manufacture of the drug.
	Hydrocortisone Acetate Suppository	Padagis US LLC	Analgesia/Addiction Other	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 2 Manufacturer contact (800) 775-2054 Hydrocortisone Acetate, Suppository, 25 mg (NDC 0574-7090-12) Discontinuation of the manufacture of the drug Hydrocortisone Acetate, Suppository, 30 mg (NDC 0574-7093-12) Discontinuation of the manufacture of the drug
	Hydromorphone Hydrochloride Suppository	Padagis US LLC	Analgesia/Addiction	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 1 Manufacturer contact (800) 775-2054 Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06) Discontinuation of the manufacture of the drug
	Morphine Sulfate Suppository	Padagis US LLC	Analgesia/Addiction	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 4 Manufacturer contact (800) 775-2054 Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12) Discontinuation of the manufacture of the drug Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12) Discontinuation of the manufacture of the drug Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12) Discontinuation of the manufacture of the drug Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12) Discontinuation of the manufacture of the drug
	Podophyllum Resin Topical Tincture	Padagis US LLC	Dermatology	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 1 Manufacturer contact (800) 775-2054 Podocon 25, Topical Tincture, 1 mg/4 mL (NDC 0574-0601-15) Discontinuation of the manufacture of the drug
	Succinylcholine Chloride Injection	Fresenius Kabi USA, LLC	Anesthesia	2026-07-23	To Be Discontinued
First posted by the FDA 2026-07-23 Presentations affected 1 Manufacturer contact 888-386-1300 Succinylcholine Chloride, Injection, 20 mg/1 mL (NDC 63323-943-10) Discontinuation of the manufacture of the drug
	Bupivacaine Hydrochloride Injection	Aspiro Pharma Limited	Anesthesia	2026-07-17	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 6 Manufacturer contact 732-529-0430, [email protected] Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32) Available Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34) Available Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32) Available Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34) Available Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32) Available Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34) Available
	Tobramycin Sulfate Injection	Hospira, Inc., a Pfizer Company	Anti-Infective	2026-07-17	To Be Discontinued
First posted by the FDA 2026-07-17 Presentations affected 1 Manufacturer contact 844-646-4398 Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01) Discontinuation of the manufacture of the drug
	Travoprost Ophthalmic Solution	Mylan Pharmaceuticals Inc., a Viatris Company	Ophthalmology	2026-07-07	To Be Discontinued
First posted by the FDA 2026-07-07 Presentations affected 2 Manufacturer contact 877-446-3679 Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32) Discontinuation of the manufacture of the drug Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50) Discontinuation of the manufacture of the drug
	Desflurane Liquid for Inhalation	Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)	Anesthesia	2026-07-02	To Be Discontinued
First posted by the FDA 2026-07-02 Presentations affected 1 Manufacturer contact Sandoz: 800-525-8747 Desflurane, Liquid for Inhalation, 240 mL/240 mL (NDC 0781-6172-86) Discontinuation of the manufacture of the drug; Distributed by Sandoz, Inc.
	Caspofungin Acetate Injection	Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)	Anti-Infective	2026-06-30	To Be Discontinued
First posted by the FDA 2026-06-30 Presentations affected 2 Manufacturer contact Sandoz: 800-525-8747 Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94) Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94) Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
	Daptomycin Injection	Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)	Anti-Infective	2026-06-30	To Be Discontinued
First posted by the FDA 2026-06-30 Presentations affected 2 Manufacturer contact 609-395-8625 ext. 203 Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01) Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc. Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1) Discontinuation of the manufacture of the drug
	Gadobutrol Injection	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Medical Imaging	2026-06-30	To Be Discontinued
First posted by the FDA 2026-06-30 Presentations affected 4 Manufacturer contact 888-386-1300 Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-02) Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-07) Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-10) Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-15) Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
	Gadoterate Meglumine Injection	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Medical Imaging	2026-06-30	To Be Discontinued
First posted by the FDA 2026-06-30 Presentations affected 4 Manufacturer contact 888-386-1800 Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05) Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10) Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15) Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20) Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug
	Lisdexamfetamine Dimesylate Capsule	Solco Healthcare US, LLC	Psychiatry	2026-06-29	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 866-931-9829 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10) Limited Availability Shortage of an active ingredient
	Oxaliplatin Injection	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Oncology	2026-06-29	To Be Discontinued
First posted by the FDA 2026-06-29 Presentations affected 2 Manufacturer contact Sagent Pharmaceuticals: 866-625-1618 Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10) Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20) Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
	Quinapril Hydrochloride Tablet	Solco Healthcare US, LLC	Cardiovascular	2026-06-29	Currently in Shortage
First posted by the FDA 2023-01-19 Presentations affected 4 Manufacturer contact 866-931-9829 Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09) Unavailable Shortage of an active ingredient Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09) Unavailable Shortage of an active ingredient Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09) Unavailable Shortage of an active ingredient Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09) Unavailable Shortage of an active ingredient
	Lisdexamfetamine Dimesylate Capsule	Rhodes Pharmaceuticals L.P.	Psychiatry	2026-06-24	Currently in Shortage
First posted by the FDA 2023-07-14 Presentations affected 7 Manufacturer contact 888-827-0616 Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01) Available Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01) Limited Availability Shortage of an active ingredient Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01) Available Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01) Limited Availability Shortage of an active ingredient
	Emtricitabine Capsule	Gilead Sciences, Inc.	Anti-Infective	2026-06-17	To Be Discontinued
First posted by the FDA 2026-06-17 Presentations affected 1 Manufacturer contact 800-445-3235 Emtriva, Capsule, 200 mg (NDC 61958-0601-1) Product expected to be available until March 2027
	Emtricitabine Oral Solution	Gilead Sciences, Inc.	Anti-Infective	2026-06-17	To Be Discontinued
First posted by the FDA 2026-06-17 Presentations affected 1 Manufacturer contact 800-445-3235 Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1) Product expected to be available until March 2027
	Etomidate Injection	Caplin Steriles, Ltd.	Anesthesia	2026-06-16	Currently in Shortage
First posted by the FDA 2022-10-05 Presentations affected 4 Manufacturer contact 908-803-2586 Etomidate, Injection, 2 mg/mL (NDC 72485-508-10) Available Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586 Etomidate, Injection, 2 mg/mL (NDC 72485-509-10) Available Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586 Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10) Available Check wholesalers for inventory; Marketed by Fresenius Kabi Etomidate, Injection, 2mg/mL (NDC 65219-447-20) Available Check wholesalers for inventory; Marketed by Fresenius Kabi
	Cefotaxime Sodium Powder, for Solution	SteriMax, Inc.	Anti-Infective Pediatric	2026-06-15	Currently in Shortage
First posted by the FDA 2015-02-17 Presentations affected 2 Manufacturer contact 800-881-3550 Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02) Available More from the FDA Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02) Available More from the FDA
	Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release	Amneal Pharmaceuticals	Neurology	2026-06-15	To Be Discontinued
First posted by the FDA 2026-06-15 Presentations affected 2 Manufacturer contact 866-525-7270 Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3) Discontinuation of the manufacture of the drug Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3) Discontinuation of the manufacture of the drug
	Lorlatinib Tablet	Pfizer Inc.	Oncology	2026-06-15	To Be Discontinued
First posted by the FDA 2026-06-15 Presentations affected 1 Manufacturer contact 800-533-4535 Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03) Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation
	Ropivacaine Hydrochloride Injection	Caplin Steriles, Ltd.	Anesthesia	2026-06-10	Currently in Shortage
First posted by the FDA 2020-12-22 Presentations affected 4 Manufacturer contact 888-229-0001 Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10) Available Check wholesalers for inventory; Marketed by Baxter Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10) Limited Availability Other Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10) Available Check wholesalers for inventory; Marketed by Baxter Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10) Limited Availability Other
	Azacitidine Injection	Armas Pharmaceuticals Inc	Oncology	2026-06-08	Currently in Shortage
First posted by the FDA 2020-12-18 Presentations affected 1 Manufacturer contact 732-637-1971 Azacitidine, Injection, 100 mg (NDC 72485-201-01) Limited Availability Other
	Dacomitinib Tablet	Pfizer Inc.	Oncology	2026-06-08	To Be Discontinued
First posted by the FDA 2026-06-08 Presentations affected 3 Manufacturer contact 800-533-4535 Vizimpro, Tablet, 15 mg (NDC 0069-0197-30) Discontinuation of the manufacture of the drug Vizimpro, Tablet, 30 mg (NDC 0069-1198-30) Discontinuation of the manufacture of the drug Vizimpro, Tablet, 45 mg (NDC 0069-2299-30) Discontinuation of the manufacture of the drug
	Leflunomide Tablet	Sanofi-Aventis U.S. LLC	Rheumatology	2026-06-08	To Be Discontinued
First posted by the FDA 2026-06-08 Presentations affected 5 Manufacturer contact 800-981-2491 Arava, Tablet, 10 mg (NDC 0088-2160-30) Discontinuation of the manufacture of the drug Arava, Tablet, 100 mg (NDC 0088-2162-33) Discontinuation of the manufacture of the drug Arava, Tablet, 20 mg (NDC 0088-2161-30) Discontinuation of the manufacture of the drug Leflunomide, Tablet, 10 mg (NDC 0955-1735-30) Discontinuation of the manufacture of the drug Leflunomide, Tablet, 20 mg (NDC 0955-1737-30) Discontinuation of the manufacture of the drug
	Dexmedetomidine Hydrochloride Injection	Slayback Pharma	Anesthesia	2026-06-05	To Be Discontinued
First posted by the FDA 2026-06-05 Presentations affected 2 Manufacturer contact 800-461-7449 Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05) Discontinuation of the manufacture of the drug Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06) Discontinuation of the manufacture of the drug
	Semaglutide Tablet	Novo Nordisk, Inc.	Endocrinology/Metabolism	2026-06-04	To Be Discontinued
First posted by the FDA 2026-06-04 Presentations affected 3 Manufacturer contact 833-493-4689 Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
	Bacitracin Ophthalmic Ointment	Padagis US LLC	Anti-Infective Ophthalmology	2026-06-01	Currently in Shortage
First posted by the FDA 2025-03-03 Presentations affected 1 Manufacturer contact 866-634-9120 Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35) Unavailable Discontinuation of the manufacture of the drug
	Carboplatin Injection	Teyro Labs	Oncology	2026-06-01	To Be Discontinued
First posted by the FDA 2026-06-01 Presentations affected 4 Manufacturer contact Apotex Inc.: 800-706-5575 Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug
	Clindamycin Phosphate Injection	Pfizer Inc.	Anti-Infective	2026-06-01	To Be Discontinued
First posted by the FDA 2026-06-01 Presentations affected 6 Manufacturer contact 844-646-4398 Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26) Discontinuation of the manufacture of the drug Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02) Discontinuation of the manufacture of the drug Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26) Discontinuation of the manufacture of the drug Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04) Discontinuation of the manufacture of the drug Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18) Discontinuation of the manufacture of the drug Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06) Discontinuation of the manufacture of the drug
	Clonazepam Tablet	Rubicon Research Private Limited	Neurology Pediatric Psychiatry	2026-06-01	Currently in Shortage
First posted by the FDA 2023-03-10 Presentations affected 11 Manufacturer contact [email protected] Clonazepam, Tablet, .5 mg (NDC 72888-152-00) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, .5 mg (NDC 72888-152-01) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, .5 mg (NDC 72888-152-05) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, .5 mg (NDC 72888-152-30) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 1 mg (NDC 72888-153-00) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 1 mg (NDC 72888-153-01) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 1 mg (NDC 72888-153-05) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 1 mg (NDC 72888-153-30) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 2 mg (NDC 72888-154-01) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 2 mg (NDC 72888-154-05) Available Marketed by Advagen Pharma Ltd. Clonazepam, Tablet, 2 mg (NDC 72888-154-30) Available Marketed by Advagen Pharma Ltd.
	Dehydrated Alcohol Injection, Solution	Accord Healthcare Inc.	Cardiovascular	2026-05-27	To Be Discontinued
First posted by the FDA 2026-05-27 Presentations affected 1 Manufacturer contact 866-941-7875 Dehydrated Alcohol, Injection, Solution, 1 mL/1 mL (10 pack) (NDC 16729-710-45) Accord is transitioning to the 5-pack configuration (NDC 16729-710-53).
	Alteplase Injection	Genentech, Inc	Cardiovascular Hematology Neurology	2026-05-21	To Be Discontinued
First posted by the FDA 2026-05-21 Presentations affected 1 Manufacturer contact 800-551-2231 Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27) Discontinuation of the 100mg vial configuration
	Iron Sucrose Injection	Mylan Institutional, a Viatris Company	Hematology	2026-05-21	To Be Discontinued
First posted by the FDA 2026-05-21 Presentations affected 1 Manufacturer contact 800-796-9526 Iron Sucrose, Injection, 50 mg/2.5 mL (NDC 67457-957-99) A business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10 Iron Sucrose 20mg/mL 5mL SDV 10PK 67457-638-25 Iron Sucrose 20mg/mL 5mL SDV 25PK.
	Activated Charcoal Oral Suspension	Padagis US LLC	Other	2026-05-15	To Be Discontinued
First posted by the FDA 2026-05-15 Presentations affected 5 Manufacturer contact 866-634-9120 Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25) Discontinuation of the manufacture of the drug Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74) Discontinuation of the manufacture of the drug Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76) Discontinuation of the manufacture of the drug Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74) Discontinuation of the manufacture of the drug Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76) Discontinuation of the manufacture of the drug
	Ketorolac Tromethamine Injection	Alembic Pharmaceuticals	Analgesia/Addiction	2026-05-15	Currently in Shortage
First posted by the FDA 2018-03-23 Presentations affected 3 Manufacturer contact 908-393-9604 Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25) Available Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25) Available Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25) Available
	Liraglutide Injection	Teva Pharmaceuticals USA, Inc.	Endocrinology/Metabolism	2026-05-14	To Be Discontinued
First posted by the FDA 2026-05-14 Presentations affected 1 Manufacturer contact 888-838-2872 Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) Discontinuation of the manufacture of the drug
	Sulconazole Nitrate Solution	Journey Medical Corporation	Dermatology	2026-05-08	To Be Discontinued
First posted by the FDA 2026-05-08 Presentations affected 3 Manufacturer contact 480-434-6670 Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30) Discontinuation of the manufacture of the drug Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05) Discontinuation of the manufacture of the drug Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30) Discontinuation of the manufacture of the drug. Manufactured for JG Pharma
	Icatibant Acetate Injection	Fresenius Kabi USA, LLC	Hematology	2026-05-07	To Be Discontinued
First posted by the FDA 2026-05-07 Presentations affected 2 Manufacturer contact 847-550-2300 Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86) Discontinuation of the manufacturer of the drug Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93) Discontinuation of the manufacturer of the drug
	Bupivacaine Hydrochloride Injection	Kindos Pharmaceuticals Co. Ltd.	Anesthesia	2026-05-05	To Be Discontinued
First posted by the FDA 2026-05-05 Presentations affected 5 Manufacturer contact 844-824-8426 Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32) Discontinuation of the manufacture of the drug Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52) Discontinuation of the manufacture of the drug Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32) Discontinuation of the manufacture of the drug Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52) Discontinuation of the manufacture of the drug Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32) Discontinuation of the manufacture of the drug
	Bupivacaine Hydrochloride Injection	Kindos Pharmaceuticals Co. Ltd.	Anesthesia	2026-05-05	Currently in Shortage
First posted by the FDA 2018-02-20 Presentations affected 5 Manufacturer contact 844-824-8426 Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32) Limited Availability Discontinuation of the manufacture of the drug More from the FDA Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52) Limited Availability Discontinuation of the manufacture of the drug More from the FDA Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32) Limited Availability Discontinuation of the manufacture of the drug More from the FDA Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52) Limited Availability Discontinuation of the manufacture of the drug More from the FDA Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32) Limited Availability Discontinuation of the manufacture of the drug More from the FDA
	Desmopressin Acetate Spray	Ferring	Hematology	2026-05-01	Currently in Shortage
First posted by the FDA 2021-03-12 Presentations affected 3 Manufacturer contact 888-337-7464 Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0) Unavailable Requirements related to complying with good manufacturing practices Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05) Unavailable Requirements related to complying with good manufacturing practices Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00) Unavailable Requirements related to complying with good manufacturing practices
	Lamotrigine Tablet, Extended Release	Par Health, Inc.	Neurology	2026-04-29	To Be Discontinued
First posted by the FDA 2026-04-29 Presentations affected 6 Manufacturer contact 800-828-9393 Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11) Discontinuation of the manufacture of the drug Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11) Discontinuation of the manufacture of the drug Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11) Discontinuation of the manufacture of the drug Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11) Discontinuation of the manufacture of the drug Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11) Discontinuation of the manufacture of the drug Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11) Discontinuation of the manufacture of the drug
	Crinecerfont Capsule	Neurocrine Biosciences, Inc.	Endocrinology/Metabolism	2026-04-28	To Be Discontinued
First posted by the FDA 2026-04-28 Presentations affected 1 Manufacturer contact 858-617-7600 Crenessity, Capsule, 25 mg (NDC 70370-5025-1) Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).
	Etravirine Tablet	Janssen Research and Development	Antiviral	2026-04-28	To Be Discontinued
First posted by the FDA 2026-04-28 Presentations affected 2 Manufacturer contact 800-526-7736 Etravirine, Tablet, 100 mg (NDC 10147-0570-1) Discontinuation of the manufacture of the drug Intelence, Tablet, 100 mg (NDC 59676-570-01) Discontinuation of the manufacture of the drug
	Furosemide Injection	Gland Pharma Limited	Cardiovascular	2026-04-28	To Be Discontinued
First posted by the FDA 2026-04-28 Presentations affected 3 Manufacturer contact Sagent Pharmaceuticals: 866-625-1618 Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
	Palbociclib Capsule	Pfizer Inc.	Oncology	2026-04-22	To Be Discontinued
First posted by the FDA 2026-04-22 Presentations affected 2 Manufacturer contact 800-533-4535 Ibrance, Capsule, 100 mg (NDC 0069-0188-21) Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured. Ibrance, Capsule, 75 mg (NDC 0069-0187-21) Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured.
	Dexmedetomidine Hydrochloride Injection	Accord Healthcare Inc.	Anesthesia	2026-04-21	To Be Discontinued
First posted by the FDA 2026-04-21 Presentations affected 1 Manufacturer contact 866-941-7875, option 2 Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93) Discontinuation of the manufacture of the drug
	Ketorolac Tromethamine Tablet	Mylan Pharmaceuticals Inc., a Viatris Company	Analgesia/Addiction	2026-04-20	To Be Discontinued
First posted by the FDA 2026-04-20 Presentations affected 1 Manufacturer contact 877-446-3679 Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01) Discontinuation of the manufacture of the drug
	Rifampin Injection	Sanofi-Aventis U.S. LLC	Anti-Infective	2026-04-20	To Be Discontinued
First posted by the FDA 2026-04-20 Presentations affected 1 Manufacturer contact 800-633-1610 Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) Discontinuation of the manufacture of the drug
	Tiagabine Hydrochloride Tablet	Teva Pharmaceuticals USA, Inc.	Neurology	2026-04-15	To Be Discontinued
First posted by the FDA 2026-04-15 Presentations affected 4 Manufacturer contact 888-838-2872 Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56) Discontinuation of the manufacture of the drug Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56) Discontinuation of the manufacture of the drug Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56) Discontinuation of the manufacture of the drug Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56) Discontinuation of the manufacture of the drug
	Nitroglycerin Ointment	AbbVie Inc.	Analgesia/Addiction	2026-04-14	To Be Discontinued
First posted by the FDA 2026-04-14 Presentations affected 1 Manufacturer contact 800-678-1605 Rectiv, Ointment, 0.4% (NDC 58914-301-80) Discontinuation of the manufacture of the drug
	Nitrofurantoin Oral Suspension	Amneal Pharmaceuticals	Anti-Infective Other	2026-04-10	To Be Discontinued
First posted by the FDA 2026-04-10 Presentations affected 1 Manufacturer contact 866-525-7270 Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9) Discontinuation of the manufacture of the drug
	Azithromycin Tablet	Pfizer Inc.	Anti-Infective	2026-04-09	To Be Discontinued
First posted by the FDA 2026-04-09 Presentations affected 2 Manufacturer contact 800-533-4535 Zithromax, Tablet, 250 mg (NDC 0069-4061-01) Discontinuation of the manufacture of the drug Zithromax, Tablet, 500 mg (NDC 0069-3070-30) Discontinuation of the manufacture of the drug
	Aprepitant Oral Powder for Suspension	Merck Sharp & Dohme LLC	Gastroenterology	2026-04-08	To Be Discontinued
First posted by the FDA 2026-04-08 Presentations affected 1 Manufacturer contact 800-672-6372 Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03) To be discontinued in approximately early-September 2026.
	Fosaprepitant Dimeglumine Injection	Fresenius Kabi USA, LLC	Gastroenterology	2026-04-08	To Be Discontinued
First posted by the FDA 2026-04-08 Presentations affected 1 Manufacturer contact 888-386-1300 Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10) Discontinuation of the manufacture of the drug
	Idelalisib Tablet	Gilead Sciences, Inc.	Oncology	2026-04-07	To Be Discontinued
First posted by the FDA 2026-04-07 Presentations affected 2 Manufacturer contact 800-445-3235 Zydelig, Tablet, 100 mg (NDC 61958-1701-1) Discontinuation in the manufacturing of the drug Zydelig, Tablet, 150 mg (NDC 61958-1702-1) Discontinuation in the manufacturing of the drug
	Ursodiol Capsule	Strides Pharma Inc.	Other	2026-04-06	To Be Discontinued
First posted by the FDA 2026-04-06 Presentations affected 1 Manufacturer contact 877-244-9825 Ursodiol, Capsule, 300 mg (NDC 64380-844-06) Discontinuation of the manufacture of the drug
	Icosapent Ethyl Capsule	Apotex Corp.	Cardiovascular	2026-04-01	To Be Discontinued
First posted by the FDA 2026-04-01 Presentations affected 2 Manufacturer contact 800-706-5575 Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12) Discontinuation of the manufacture of the drug Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1) Discontinuation of the manufacture of the drug
	Dapsone Gel	Amneal Pharmaceuticals	Dermatology	2026-03-27	To Be Discontinued
First posted by the FDA 2026-03-27 Presentations affected 1 Manufacturer contact 866-525-7270 Dapsone, Gel, 7.5% (NDC 69238-1627-6) Discontinuation of the manufacture of the drug
	Progesterone Vaginal Gel	AbbVie Inc.	Urology	2026-03-27	To Be Discontinued
First posted by the FDA 2026-03-27 Presentations affected 1 Manufacturer contact 800-678-1605 Crinone, Vaginal Gel, 4% (NDC 0023-6150-04) Discontinuation of the manufacture of the drug
	Tazemetostat Hydrobromide Tablet	Epizyme, Inc. (An Ipsen Company)	Oncology	2026-03-27	To Be Discontinued
First posted by the FDA 2026-03-27 Presentations affected 1 Manufacturer contact (855)-463-5127 Tazverik, Tablet, 200 mg (NDC 72607-100-00) Discontinuation of the manufacture of the drug product
	Clindamycin Palmitate Hydrochloride Injection	Amneal Pharmaceuticals	Anti-Infective	2026-03-26	To Be Discontinued
First posted by the FDA 2026-03-26 Presentations affected 1 Manufacturer contact 866-525-7270 Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) Discontinuation of the manufacture of the drug
	Lincomycin Hydrochloride Injection	XGen Pharmaceuticals DJB, Inc.	Anti-Infective	2026-03-26	To Be Discontinued
First posted by the FDA 2026-03-26 Presentations affected 2 Manufacturer contact 866-390-4411 Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6) A business decision was made to discontinue manufacture of the drug. Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2) A business decision was made to discontinue manufacture of the drug.
	Nebivolol Hydrochloride Tablet	Torrent Pharmaceuticals Limited	Cardiovascular	2026-03-25	To Be Discontinued
First posted by the FDA 2026-03-25 Presentations affected 16 Manufacturer contact 908-280-3333 Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30) Discontinuation of the manufacture of the drug Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90) Discontinuation of the manufacture of the drug
	Ivabradine Hydrochloride Tablet	Amgen Inc.	Cardiovascular	2026-03-24	To Be Discontinued
First posted by the FDA 2026-03-24 Presentations affected 2 Manufacturer contact 1-800-772-6436 Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60) Discontinuation of the manufacture of the drug product Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60) Discontinuation of the manufacture of the drug product
	Ivabradine Solution	Amgen Inc.	Cardiovascular	2026-03-24	To Be Discontinued
First posted by the FDA 2026-03-24 Presentations affected 1 Manufacturer contact 1-800-772-6436 Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28) Discontinuation of the manufacture of the drug product
	Pilocarpine Hydrochloride Ophthalmic Solution	AbbVie Inc.	Ophthalmology	2026-03-24	To Be Discontinued
First posted by the FDA 2026-03-24 Presentations affected 5 Manufacturer contact 800-633-9110 Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01) Discontinuation of the manufacture of the drug Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03) Discontinuation of the manufacture of the drug Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04) Discontinuation of the manufacture of the drug Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05) Discontinuation of the manufacture of the drug Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06) Discontinuation of the manufacture of the drug
	Pentamidine Isethionate Injection	XGen Pharmaceuticals DJB, Inc.	Anti-Infective	2026-03-23	To Be Discontinued
First posted by the FDA 2026-03-23 Presentations affected 1 Manufacturer contact 866-390-4411 Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2) A business decision was made to discontinue manufacture of the drug.
	Ramelteon Tablet	Takeda Pharmaceuticals USA Inc.	Psychiatry	2026-03-19	To Be Discontinued
First posted by the FDA 2026-03-19 Presentations affected 2 Manufacturer contact 877-825-3327 Rozerem, Tablet, 8 mg (NDC 64764-805-10) Product is expected to be available through February 2027. Rozerem, Tablet, 8 mg (NDC 64764-805-30) Product is expected to be available through June 2027.
	Plerixafor Injection	Fresenius Kabi USA, LLC	Hematology	2026-03-13	To Be Discontinued
First posted by the FDA 2026-03-13 Presentations affected 1 Manufacturer contact 888-391-6300 www.fresenius-kabi.com Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12) A business decision was made to discontinue manufacture of the drug.
	Peritoneal Dialysis Solution	Fresenius Medical Care North America	Renal	2026-03-10	To Be Discontinued
First posted by the FDA 2026-03-10 Presentations affected 6 Manufacturer contact 800-323-5188 DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94) The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92) The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94) The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92) The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94) The NDC codes are being discontinued, to be replaced with NDC labeler code #46163. DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92) The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
	Everolimus Tablet	Teva Pharmaceuticals USA, Inc.	Transplant	2026-03-02	To Be Discontinued
First posted by the FDA 2026-03-02 Presentations affected 4 Manufacturer contact 800-545-8800 Everolimus, Tablet, 10 mg (NDC 0093-7769-24) Discontinuation of the manufacture of the drug Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24) Discontinuation of the manufacture of the drug Everolimus, Tablet, 5 mg (NDC 0093-7767-24) Discontinuation of the manufacture of the drug Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24) Discontinuation of the manufacture of the drug
	Itraconazole Capsule	Janssen Pharmaceuticals	Anti-Infective Other	2026-02-27	To Be Discontinued
First posted by the FDA 2026-02-27 Presentations affected 3 Manufacturer contact 800-JANSSEN (1-800-526-7736) Sporanox, Capsule, 100 mg (NDC 10147-1700-3) Discontinuation of the manufacture of the drug Sporanox, Capsule, 100 mg (NDC 50458-290-01) Discontinuation of the manufacture of the drug Sporanox, Capsule, 100 mg (NDC 50458-290-04) Discontinuation of the manufacture of the drug
	Clindamycin Hydrochloride Capsule	Pfizer Inc.	Anti-Infective	2026-02-25	To Be Discontinued
First posted by the FDA 2026-02-25 Presentations affected 3 Manufacturer contact 844-646-4398 Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02) Discontinuation of the manufacture of the drug Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14) Discontinuation of the manufacture of the drug Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02) Discontinuation of the manufacture of the drug
	Lincomycin Hydrochloride Injection	Pfizer Inc.	Anti-Infective	2026-02-25	To Be Discontinued
First posted by the FDA 2026-02-25 Presentations affected 1 Manufacturer contact 844-646-4398 Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04) Discontinuation of the manufacture of the drug
	Oxaliplatin Injection	Fresenius Kabi USA, LLC	Oncology	2026-02-25	To Be Discontinued
First posted by the FDA 2026-02-25 Presentations affected 2 Manufacturer contact 847-550-2300 Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10) A business decision was made to discontinue manufacture of the drug. Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20) A business decision was made to discontinue manufacture of the drug.
	Arsenic Trioxide Injection	Ingenus Pharmaceuticals LLC	Oncology	2026-02-24	To Be Discontinued
First posted by the FDA 2026-02-24 Presentations affected 1 Manufacturer contact 866-321-5031 Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10) A business decision was made to discontinue manufacture of the drug.
	Frovatriptan Succinate Tablet	Endo Pharmaceuticals, Inc.	Neurology	2026-02-24	To Be Discontinued
First posted by the FDA 2025-11-12 Presentations affected 2 Manufacturer contact 800-828-9393 Frova, Tablet, 2.5 mg (NDC 63481-025-09) A business decision was made to discontinue manufacture of the drug. Frova, Tablet, 2.5 mg (NDC 0603-3718-34) A business decision was made to discontinue manufacture of the drug.
	Irinotecan Hydrochloride Injection	Ingenus Pharmaceuticals LLC	Oncology	2026-02-24	To Be Discontinued
First posted by the FDA 2026-02-24 Presentations affected 2 Manufacturer contact 866-321-5031 Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05) A business decision was made to discontinue manufacture of the drug. Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02) A business decision was made to discontinue manufacture of the drug.
	Carboplatin Injection	Ingenus Pharmaceuticals LLC	Oncology	2026-02-20	To Be Discontinued
First posted by the FDA 2026-02-20 Presentations affected 2 Manufacturer contact 866-321-5031 Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) Discontinuation of the manufacture of the drug Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) Discontinuation of the manufacture of the drug
	Decitabine Injection	Ingenus Pharmaceuticals LLC	Oncology	2026-02-20	To Be Discontinued
First posted by the FDA 2026-02-20 Presentations affected 2 Manufacturer contact 866-321-5031 Decitabine, Injection, 50 mg (NDC 50742-430-01) Discontinuation of the manufacture of the drug Decitabine, Injection, 50 mg (NDC 68001-573-41) Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug
	Docetaxel Injection	Ingenus Pharmaceuticals LLC	Oncology	2026-02-20	To Be Discontinued
First posted by the FDA 2026-02-20 Presentations affected 2 Manufacturer contact 866-321-5031 Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08) A business decision was made to discontinue manufacture of the drug. Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16) A business decision was made to discontinue manufacture of the drug.
	Allopurinol Tablet	Teva Pharmaceuticals USA, Inc.	Oncology Renal Rheumatology	2026-02-19	To Be Discontinued
First posted by the FDA 2026-02-19 Presentations affected 4 Manufacturer contact 800-545-8800 Allopurinol, Tablet, 100 mg (NDC 0591-5543-01) Discontinuation of the manufacture of the drug Allopurinol, Tablet, 100 mg (NDC 0591-5543-10) Discontinuation of the manufacture of the drug Allopurinol, Tablet, 300 mg (NDC 0591-5544-01) Discontinuation of the manufacture of the drug Allopurinol, Tablet, 300 mg (NDC 0591-5544-05) Discontinuation of the manufacture of the drug
	Cefepime Hydrochloride Injection	Fresenius Kabi USA, LLC	Anti-Infective	2026-02-10	To Be Discontinued
First posted by the FDA 2026-02-10 Presentations affected 2 Manufacturer contact 888-386-1300 Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20) Discontinuation of the manufacture of the drug. Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20) Discontinuation of the manufacture of the drug.
	Chlorothiazide Oral Suspension	Salix Pharmaceuticals, a division of Bausch Health US, LLC	Cardiovascular	2026-02-10	To Be Discontinued
First posted by the FDA 2026-02-10 Presentations affected 1 Manufacturer contact 800-321-4576 Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12)
	Gemfibrozil Tablet	Pfizer Inc.	Endocrinology/Metabolism	2026-02-10	To Be Discontinued
First posted by the FDA 2026-02-10 Presentations affected 1 Manufacturer contact 800-533-4535 Lopid, Tablet, 600 mg (NDC 0071-0737-20) Discontinuation of the manufacture of the drug.
	Pindolol Tablet	Sun Pharmaceutical Industries, Inc.	Cardiovascular	2026-01-30	To Be Discontinued
First posted by the FDA 2026-01-30 Presentations affected 2 Manufacturer contact 800-818-4555 Pindolol, Tablet, 10 mg (NDC 57664-656-88) Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026 Pindolol, Tablet, 5 mg (NDC 57664-655-88) Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027
	Podofilox Topical Gel	AbbVie Inc.	Dermatology Other	2026-01-28	To Be Discontinued
First posted by the FDA 2026-01-28 Presentations affected 1 Manufacturer contact 800-633-9110 Condylox , Topical Gel, 0.5% (NDC 0023-6118-03) Discontinuation of the manufacture of the drug
	Benztropine Mesylate Injection	Fresenius Kabi USA, LLC	Neurology	2026-01-27	To Be Discontinued
First posted by the FDA 2026-01-27 Presentations affected 1 Manufacturer contact 888-386-1300 Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02) Discontinuation of the manufacture of the drug
	Fluvastatin Sodium Tablet, Extended Release	Sandoz Inc.	Cardiovascular	2026-01-27	To Be Discontinued
First posted by the FDA 2026-01-27 Presentations affected 3 Manufacturer contact 800-525-8747 Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01) Discontinuation of the manufacture of the drug Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31) Discontinuation of the manufacture of the drug Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31) Discontinuation of the manufacture of the drug
	Azithromycin Injection	Pfizer Inc.	Anti-Infective	2026-01-20	To Be Discontinued
First posted by the FDA 2026-01-20 Presentations affected 1 Manufacturer contact 844-646-4398 Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83) Discontinuation of the manufacture of the drug.
	Maraviroc Solution	ViiV Healthcare Company	Antiviral	2026-01-20	To Be Discontinued
First posted by the FDA 2026-01-20 Presentations affected 1 Manufacturer contact 877-844-8872 Selzentry, Solution, 20 mg/mL Oral Solution Kit \| 230 mL Oral Solution per Bottle \| 1 Bottle per Carton (NDC 49702-260-55) The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.
	Piperacillin and Tazobactam Injection	Fresenius Kabi USA, LLC	Anti-Infective	2026-01-20	To Be Discontinued
First posted by the FDA 2026-01-20 Presentations affected 1 Manufacturer contact 888-386-1300 Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20) Discontinuation of the manufacture of the drug
	Riboflavin 5-phosphate Ophthalmic Solution	Glaukos Corporation	Ophthalmology	2026-01-20	To Be Discontinued
First posted by the FDA 2026-01-20 Presentations affected 1 Manufacturer contact 949-367-9600 Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03) Discontinuing manufacture of the product as of July 2026.
	Adalimumab-adaz Injection	Sandoz Inc.	Rheumatology	2026-01-13	To Be Discontinued
First posted by the FDA 2026-01-13 Presentations affected 5 Manufacturer contact 800-525-8747 Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) Equivalent Sandoz format is available. Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36) Equivalent Sandoz format is available. Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68) Equivalent Sandoz format is available. Hyrimoz, Injection, Kit (NDC 61314-517-36) Equivalent Sandoz format is available. Hyrimoz, Injection, Kit (NDC 61314-531-64) Equivalent Sandoz format is available.
	Caspofungin Acetate Injection	Fresenius Kabi USA, LLC	Anti-Infective	2026-01-12	To Be Discontinued
First posted by the FDA 2026-01-12 Presentations affected 1 Manufacturer contact 888-386-1300 Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) Discontinuation of the manufacture of the drug
	Doxycycline Hyclate Tablet	Mylan Pharmaceuticals Inc., a Viatris Company	Anti-Infective	2026-01-12	To Be Discontinued
First posted by the FDA 2026-01-12 Presentations affected 2 Manufacturer contact 800-796-9526 Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02) Discontinuation of the manufacture of the drug Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13) Discontinuation of the manufacture of the drug
	Doxylamine Succinate and Pyridoxine Hydrochloride Tablet, Delayed Release	Mylan Pharmaceuticals Inc., a Viatris Company	Other	2026-01-12	To Be Discontinued
First posted by the FDA 2026-01-12 Presentations affected 1 Manufacturer contact 800-796-9526 Doxylamine Succinate and Pyridoxine Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg (NDC 0378-4615-01) A business decision was made to discontinue manufacture of the drug.
	Neostigmine Methylsulfate Injection	Fresenius Kabi USA, LLC	Analgesia/Addiction	2026-01-12	To Be Discontinued
First posted by the FDA 2026-01-12 Presentations affected 1 Manufacturer contact 888-386-1300 Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10) Discontinuation of the manufacture of the drug
	Haloperidol Decanoate Injection	Fresenius Kabi USA, LLC	Psychiatry	2026-01-09	To Be Discontinued
First posted by the FDA 2026-01-09 Presentations affected 2 Manufacturer contact 888-386-1300 Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01) Discontinuation of the manufacture of the drug Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05) Discontinuation of the manufacture of the drug
	Imipenem and Cilastatin Injection	Merck Sharp & Dohme Corp.	Anti-Infective	2026-01-08	To Be Discontinued
First posted by the FDA 2026-01-08 Presentations affected 1 Manufacturer contact 800-672-6372 Primaxin, Injection, 500mg (NDC 0006-3516-59) To be discontinued approximately 11/30/2026
	Everolimus Tablet	Endo Pharmaceuticals, Inc.	Transplant	2026-01-06	To Be Discontinued
First posted by the FDA 2026-01-06 Presentations affected 4 Manufacturer contact 800-828-9393 Everolimus, Tablet, 10 mg (NDC 49884-128-91) Discontinuation of the manufacture of the drug Everolimus, Tablet, 2.5 mg (NDC 49884-119-91) Discontinuation of the manufacture of the drug Everolimus, Tablet, 5 mg (NDC 49884-125-91) Discontinuation of the manufacture of the drug Everolimus, Tablet, 7.5 mg (NDC 49884-127-91) Discontinuation of the manufacture of the drug
	Diltiazem Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Cardiovascular	2026-01-05	To Be Discontinued
First posted by the FDA 2026-01-05 Presentations affected 1 Manufacturer contact 844-646-4398 Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03) Discontinuation of the manufacture of the drug
	Hydroxychloroquine Sulfate Tablet	Teva Pharmaceuticals USA, Inc.	Anti-Infective Other Rheumatology	2026-01-05	To Be Discontinued
First posted by the FDA 2026-01-05 Presentations affected 1 Manufacturer contact 800-545-8800 Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01) Discontinuation of the manufacture of the drug
	Sodium Oxybate Solution	Amneal Pharmaceuticals	Psychiatry	2025-12-29	To Be Discontinued
First posted by the FDA 2025-12-29 Presentations affected 1 Manufacturer contact 800-525-7270 Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1) Discontinuation of the manufacture of the drug
	Mirikizumab-mrkz Injection	Eli Lilly and Co.	Gastroenterology Other	2025-12-22	To Be Discontinued
First posted by the FDA 2025-12-22 Presentations affected 2 Manufacturer contact 800-545-5979 Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27) A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain. Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27) A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
	Morphine Sulfate Tablet	Upsher-Smith Laboratories, LLC	Analgesia/Addiction	2025-12-22	To Be Discontinued
First posted by the FDA 2025-12-22 Presentations affected 2 Manufacturer contact 763-315-2000 Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11) Discontinuation of the manufacture of the drug Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11) Discontinuation of the manufacture of the drug
	Carbamazepine Capsule, Extended Release	Takeda Pharmaceuticals USA Inc.	Neurology	2025-12-19	To Be Discontinued
First posted by the FDA 2025-12-19 Presentations affected 3 Manufacturer contact 855-268-1825 Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12) Discontinuation of the manufacture of the drug Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12) Discontinuation of the manufacture of the drug Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12) Discontinuation of the manufacture of the drug
	Doxercalciferol Injection	Sanofi-Aventis U.S. LLC	Endocrinology/Metabolism	2025-12-10	To Be Discontinued
First posted by the FDA 2025-12-10 Presentations affected 3 Manufacturer contact 800-633-1610 Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1) Discontinuation of the manufacture of the drug Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1) Discontinuation of the manufacture of the drug Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1) Discontinuation of the manufacture of the drug
	Spironolactone Tablet	Pfizer Inc.	Cardiovascular	2025-12-10	To Be Discontinued
First posted by the FDA 2025-12-10 Presentations affected 2 Manufacturer contact 800-533-4535 Aldactone, Tablet, 100 mg (NDC 0025-1031-31) Discontinuation of the manufacture of the drug. Aldactone, Tablet, 25 mg (NDC 0025-1001-31) Discontinuation of the manufacture of the drug.
	Ampicillin Sodium Injection	Sandoz Inc.	Anti-Infective	2025-12-08	To Be Discontinued
First posted by the FDA 2025-12-08 Presentations affected 5 Manufacturer contact 800-525-8747 Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95) Discontinuation of private label only Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92) Discontinuation of private label only Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95) Discontinuation of private label only Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95) Discontinuation of private label only Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92) Discontinuation of private label only
	Calcitriol Capsule	Teva Pharmaceuticals USA, Inc.	Endocrinology/Metabolism	2025-12-04	To Be Discontinued
First posted by the FDA 2025-12-04 Presentations affected 2 Manufacturer contact 800-545-8800 Calcitriol, Capsule, .25 ug (NDC 0093-7352-01) A business decision was made to discontinue manufacture of the drug Calcitriol, Capsule, .5 ug (NDC 0093-7353-01) A business decision was made to discontinue manufacture of the drug
	Sodium Chloride 0.9% Injection	Hospira, Inc., a Pfizer Company	Gastroenterology Other Renal	2025-12-03	To Be Discontinued
First posted by the FDA 2025-12-03 Presentations affected 3 Manufacturer contact 844-646-4398 Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67) Discontinuation of the manufacture of the drug Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02) Discontinuation of the manufacture of the drug Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66) Discontinuation of the manufacture of the drug
	Posaconazole Injection	Merck Sharp & Dohme Corp.	Anti-Infective	2025-12-02	To Be Discontinued
First posted by the FDA 2025-12-02 Presentations affected 1 Manufacturer contact 800-672-6372 Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01) Discontinuation of the manufacture of the drug
	Nilutamide Tablet	Advanz Pharma (US) Corp.	Oncology	2025-12-01	To Be Discontinued
First posted by the FDA 2025-12-01 Presentations affected 2 Manufacturer contact 847-283-7921 Nilandron, Tablet, 150 mg (NDC 59212-111-14) Product to expire in March 2026; Discontinuation of the manufacture of the drug Nilandron, Tablet, 150 mg (NDC 66993-212-38) Product to expire in March 2026; Discontinuation of the manufacture of the drug
	Phenoxybenzamine Hydrochloride Capsule	Advanz Pharma (US) Corp.	Cardiovascular	2025-12-01	To Be Discontinued
First posted by the FDA 2025-12-01 Presentations affected 3 Manufacturer contact 847-283-7921 Dibenzyline, Capsule, 10 mg (NDC 59212-001-01) Discontinuation of the manufacture of the drug Dibenzyline, Capsule, 10 mg (NDC 59212-001-02) Discontinuation of the manufacture of the drug Dibenzyline, Capsule, 10 mg (NDC 66993-066-02) Discontinuation of the manufacture of the drug
	Potassium Chloride Tablet, Extended Release	Teva Pharmaceuticals USA, Inc.	Endocrinology/Metabolism Gastroenterology	2025-11-21	To Be Discontinued
First posted by the FDA 2025-11-21 Presentations affected 4 Manufacturer contact 800-545-8800 Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01) Discontinuation of the manufacture of the drug Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01) Discontinuation of the manufacture of the drug Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05) Discontinuation of the manufacture of the drug Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10) Discontinuation of the manufacture of the drug
	Verapamil Hydrochloride Injection	Pfizer Inc.	Cardiovascular	2025-11-21	To Be Discontinued
First posted by the FDA 2025-11-21 Presentations affected 1 Manufacturer contact 844-646-4398 Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05) Discontinuation of the manufacture of the drug
	Anagrelide Hydrochloride Capsule	Teva Pharmaceuticals USA, Inc.	Hematology	2025-11-19	To Be Discontinued
First posted by the FDA 2025-11-19 Presentations affected 2 Manufacturer contact 800-545-8800 Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60) A business decision was made to discontinue manufacture of the drug. Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60) A business decision was made to discontinue manufacture of the drug.
	Hydrochlorothiazide Capsule	Teva Pharmaceuticals USA, Inc.	Cardiovascular	2025-11-19	To Be Discontinued
First posted by the FDA 2025-11-19 Presentations affected 2 Manufacturer contact 800-545-8800 Microzide, Capsule, 12.5 mg (NDC 0591-0347-01) A business decision was made to discontinue manufacture of the drug. Microzide, Capsule, 12.5 mg (NDC 0591-0347-05) A business decision was made to discontinue manufacture of the drug.
	Valsartan Tablet	Mylan Pharmaceuticals Inc., a Viatris Company	Cardiovascular	2025-11-19	To Be Discontinued
First posted by the FDA 2025-11-19 Presentations affected 4 Manufacturer contact 800-796-9526 Valsartan, Tablet, 160 mg (NDC 0378-5814-77) A business decision was made to discontinue manufacture of the drug. Valsartan, Tablet, 320 mg (NDC 0378-5815-77) A business decision was made to discontinue manufacture of the drug. Valsartan, Tablet, 40 mg (NDC 0378-5807-93) A business decision was made to discontinue manufacture of the drug. Valsartan, Tablet, 80 mg (NDC 0378-5813-77) A business decision was made to discontinue manufacture of the drug.
	Montelukast Sodium Tablet, Chewable	Organon	Pulmonary/Allergy	2025-11-17	To Be Discontinued
First posted by the FDA 2025-11-17 Presentations affected 1 Manufacturer contact 844-674-3200 Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01) Discontinuation of the manufacture of the drug
	Ceftazidime Injection	Hospira, Inc., a Pfizer Company	Anti-Infective	2025-11-14	To Be Discontinued
First posted by the FDA 2025-11-14 Presentations affected 2 Manufacturer contact 844-646-4398 Tazicef, Injection, 1 g (NDC 0409-5092-16) Discontinuation of the manufacture of the drug Tazicef, Injection, 2 g (NDC 0409-5093-11) Discontinuation of the manufacture of the drug
	Palonosetron Hydrochloride Injection	Teva Pharmaceuticals USA, Inc.	Gastroenterology	2025-11-14	To Be Discontinued
First posted by the FDA 2025-11-14 Presentations affected 1 Manufacturer contact 800-545-8800 Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01) Discontinuation of the manufacture of the drug
	Somatropin Injection	Novo Nordisk, Inc.	Endocrinology/Metabolism	2025-11-14	To Be Discontinued
First posted by the FDA 2025-11-14 Presentations affected 1 Manufacturer contact 833-493-4689 Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) Discontinuation of the manufacture of the drug
	Vancomycin Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Anti-Infective	2025-11-14	To Be Discontinued
First posted by the FDA 2025-11-14 Presentations affected 1 Manufacturer contact 844-646-4398 Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01) Discontinuation of the manufacture of the drug
	Adalimumab-ryvk Kit	Teva Pharmaceuticals USA, Inc.	Rheumatology	2025-11-13	To Be Discontinued
First posted by the FDA 2025-11-13 Presentations affected 1 Manufacturer contact 800-545-8800 Simlandi, Kit, Kit (NDC 51759-523-21) Discontinuation of the manufacture of the drug
	Cetrorelix Acetate Injection	Teva Pharmaceuticals USA, Inc.	Reproductive	2025-11-13	To Be Discontinued
First posted by the FDA 2025-11-13 Presentations affected 1 Manufacturer contact 800-545-8800 Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08) Discontinuation of the manufacture of the drug
	Guanfacine Hydrochloride Tablet, Extended Release	Actavis Pharma, Inc.	Psychiatry	2025-11-13	To Be Discontinued
First posted by the FDA 2025-11-13 Presentations affected 4 Manufacturer contact 800-545-8800 Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11) A business decision was made to discontinue manufacture of the drug. Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11) A business decision was made to discontinue manufacture of the drug. Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11) A business decision was made to discontinue manufacture of the drug. Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11) A business decision was made to discontinue manufacture of the drug.
	Atropine Sulfate Injection	Hospira, Inc., a Pfizer Company	Anesthesia Neurology Pediatric	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 2 Manufacturer contact 844-646-4398 Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)" Discontinuation of the manufacture of the drug Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)" Discontinuation of the manufacture of the drug
	Calcium Chloride Injection	Hospira, Inc., a Pfizer Company	Cardiovascular Endocrinology/Metabolism	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 1 Manufacturer contact 844-646-4398 Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34) Discontinuation of the manufacture of the drug
	Deferiprone Tablet	Chiesi USA, Inc.	Hematology	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 1 Manufacturer contact 888-466-6505 Ferriprox, Tablet, 500 mg (NDC 10122-100-10) Discontinuation of the manufacture of the drug.
	Dextrose Monohydrate 50% Injection	Hospira, Inc., a Pfizer Company	Endocrinology/Metabolism Gastroenterology Pediatric	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 1 Manufacturer contact 844-646-4398 Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34) Discontinuation of the manufacture of the drug
	Epinephrine Injection	Hospira, Inc., a Pfizer Company	Cardiovascular Endocrinology/Metabolism	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 2 Manufacturer contact 844-646-4398 Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01) Discontinuation of the manufacture of the drug Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10) Discontinuation of the manufacture of the drug
	Ketamine Hydrochloride Injection	Pfizer Inc.	Anesthesia	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 1 Manufacturer contact 844-646-4398 Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10) Discontinuation of the manufacture of the drug
	Lidocaine Hydrochloride Injection	Hospira, Inc., a Pfizer Company	Analgesia/Addiction Anesthesia Pediatric	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 2 Manufacturer contact 844-646-4398 Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)" Discontinuation of the manufacture of the drug Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)" Discontinuation of the manufacture of the drug
	Sodium Bicarbonate Injection	Hospira, Inc., a Pfizer Company	Endocrinology/Metabolism Gastroenterology Pediatric	2025-11-07	To Be Discontinued
First posted by the FDA 2025-11-07 Presentations affected 4 Manufacturer contact 844-646-4398 Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14) Discontinuation of the manufacture of the drug Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14) Discontinuation of the manufacture of the drug Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14) Discontinuation of the manufacture of the drug Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14) Discontinuation of the manufacture of the drug
	Acetaminophen; Oxycodone Hydrochloride Tablet	Endo Pharmaceuticals, Inc.	Analgesia/Addiction	2025-11-03	To Be Discontinued
First posted by the FDA 2025-11-03 Presentations affected 6 Manufacturer contact 800-828-9393 Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70) Discontinuation of the manufacture of the drug Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70) Discontinuation of the manufacture of the drug Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70) Discontinuation of the manufacture of the drug Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70) Discontinuation of the manufacture of the drug Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85) Discontinuation of the manufacture of the drug Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70) Discontinuation of the manufacture of the drug
	Atazanavir Sulfate; Cobicistat Tablet	Bristol Myers Squibb Co.	Antiviral	2025-11-03	To Be Discontinued
First posted by the FDA 2025-11-03 Presentations affected 1 Manufacturer contact 800-332-2056 Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11) The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
	Everolimus Tablet	Mylan Pharmaceuticals Inc., a Viatris Company	Transplant	2025-11-03	To Be Discontinued
First posted by the FDA 2025-11-03 Presentations affected 3 Manufacturer contact 800-796-9526 Everolimus, Tablet, 2 mg (NDC 0378-0005-85) Discontinuation of the manufacture of the drug Everolimus, Tablet, 3 mg (NDC 0378-0006-85) Discontinuation of the manufacture of the drug Everolimus, Tablet, 5 mg (NDC 0378-0007-85) Discontinuation of the manufacture of the drug
	Lasmiditan Succinate Tablet	Eli Lilly and Co.	Neurology	2025-11-03	To Be Discontinued
First posted by the FDA 2025-11-03 Presentations affected 6 Manufacturer contact 800-545-5979 Reyvow, Tablet, 100 mg (NDC 0002-4491-08) A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. Reyvow, Tablet, 100 mg (NDC 0002-4491-61) A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. Reyvow, Tablet, 100 mg (NDC 0002-4491-62) A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. Reyvow, Tablet, 50 mg (NDC 0002-4312-08) A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. Reyvow, Tablet, 50 mg (NDC 0002-4312-61) A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. Reyvow, Tablet, 50 mg (NDC 0002-4312-62) A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
	Scopolamine Transdermal System	Padagis US LLC	Gastroenterology Neurology Other	2025-11-03	To Be Discontinued
First posted by the FDA 2025-11-03 Presentations affected 1 Manufacturer contact 866-634-9120 Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46) Discontinuation of the manufacture of the drug
	Phenobarbital Tablet	Endo Pharmaceuticals, Inc.	Analgesia/Addiction Neurology Other	2025-10-31	To Be Discontinued
First posted by the FDA 2025-10-31 Presentations affected 8 Manufacturer contact 800-828-9393 Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21) Discontinuation of the manufacture of the drug Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32) Discontinuation of the manufacture of the drug
	Moxifloxacin Injection	Fresenius Kabi USA, LLC	Anti-Infective	2025-10-29	To Be Discontinued
First posted by the FDA 2025-10-29 Presentations affected 1 Manufacturer contact 888-386-1300 Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74) Discontinuation of the manufacture of the drug
	Pramlintide Acetate Injection	AstraZeneca AB	Endocrinology/Metabolism	2025-10-27	To Be Discontinued
First posted by the FDA 2025-10-27 Presentations affected 2 Manufacturer contact 800-236-9933 SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02) Discontinuation of the manufacture of the drug. SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02) Discontinuation of the manufacture of the drug.
	Busulfan Injection	Mylan Institutional, a Viatris Company	Hematology	2025-10-24	To Be Discontinued
First posted by the FDA 2025-10-24 Presentations affected 1 Manufacturer contact 800-796-9526 Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08) Discontinuation of the manufacture of the drug.
	Insulin Glargine Injection	Eli Lilly and Co.	Endocrinology/Metabolism	2025-10-24	To Be Discontinued
First posted by the FDA 2025-10-24 Presentations affected 1 Manufacturer contact 800-545-5979 Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05) A business decision was made to discontinue manufacture of the drug.
	Insulin Lispro-aabc Injection	Eli Lilly and Co.	Endocrinology/Metabolism	2025-10-24	To Be Discontinued
First posted by the FDA 2025-10-24 Presentations affected 2 Manufacturer contact 800-545-5979 Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) A business decision was made to discontinue manufacture of the drug. Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) A business decision was made to discontinue manufacture of the drug.
	Prazosin Hydrochloride Capsule	Pfizer Inc.	Cardiovascular	2023-04-28	To Be Discontinued
First posted by the FDA 2023-04-28 Presentations affected 3 Manufacturer contact 800-533-4535 Minipress, Capsule, 1 mg (NDC 0069-4310-71) Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023 Minipress, Capsule, 2 mg (NDC 0069-4370-71) Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023 Minipress, Capsule, 5 mg (NDC 0069-4380-71) Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023

/* Without JS the expanders can't work: show every detail row inline and hide the controls that depend on the script. */ .shortages-table__detail[hidden] { display: table-row; } .shortages-table__expander, .shortages-table__export { display: none; }

About

About the FDA drug shortage list

BuyandBill.com publishes the FDA's drug shortages on a daily basis. Our data comes directly from the FDA's Drug Shortages Staff (DSS), the team responsible for tracking, preventing, and helping to resolve shortages of medically necessary drugs.

The table covers three kinds of status: drugs currently in shortage, drugs whose shortage has been resolved, and products that manufacturers have reported they intend to discontinue.

The process

How the FDA tracks and resolves a shortage

A shortage moves through a defined path, from the manufacturer's first notification to the FDA confirming that supply has recovered.

Manufacturer notification

Under the FDA Safety and Innovation Act, manufacturers must notify the FDA of a permanent discontinuance or a temporary interruption in supply, generally at least six months in advance.
FDA assessment

The Drug Shortages Staff (DSS) evaluate the supply situation, confirm whether demand exceeds available supply, and add the affected product to the shortage list.
Mitigation

The FDA works with manufacturers to address the underlying cause, and may expedite review of related submissions or use regulatory flexibility to help restore supply.
Resolution

Once manufacturers confirm that supply can again meet demand, the DSS marks the shortage resolved and the listing is updated.

FAQ

Frequently asked questions

What is a drug shortage?

The FDA defines a drug shortage as a period when the demand or projected demand for a drug within the United States exceeds its supply. Shortages can affect any drug, but they are especially disruptive for office-administered, buy-and-bill products that providers must keep on hand.

Where does BuyandBill.com's shortage data come from?

All of the data on this page is sourced from the FDA's Drug Shortages Staff (DSS), the team within the Center for Drug Evaluation and Research that tracks, prevents, and helps resolve shortages. BuyandBill.com refreshes the list daily so the status of each product stays current.

What is the difference between a shortage and a discontinuation?

A shortage is a temporary gap between supply and demand that the FDA expects manufacturers to resolve. A discontinuation is a manufacturer permanently removing a product from the market. Manufacturers are required to report planned discontinuances to the FDA in advance.

Why do drug shortages happen?

Common causes include manufacturing and product-quality problems, production delays, shortages of raw materials or active ingredients, business decisions to discontinue a product, and unexpected surges in demand.

How do shortages affect buy and bill?

When an office-administered drug is in shortage or discontinued, providers may have to substitute an alternative product. That substitution can change the NDC, the HCPCS code billed, and the resulting reimbursement.

Manufacturer notification

FDA assessment

Mitigation

Resolution

Frequently asked questions